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McClaughry, Anne E. M.S., May 2005 HHP: Exercise Physiology
Effects of Carbohydrate Feeding on Muscle Glycogen and Substrate Oxidation During 
Extended Exercise in Females
Chairperson: Brent C. Rub^^^^^^y
Previous research has demonstrated that regular carbohydrate feedings during exercise 
have limited effects on the preservation of muscle glycogen. However, the majority o f 
this work includes exercise less than three hours in duration and has been conducted on 
males. PURPOSE: To determine the effects of CHO feeding during 10-hours of 
moderate exercise on muscle glycogen and substrate utilization in females. METHODS: 
Six moderately trained females (age 23±3 yr, eumenorrheic and not taking oral 
contraceptives) served as subjects. Subjects performed a GXT on a treadmill (TM) and 
on an electronically braked cycle ergometer (C) to determine ventilatory threshold (VT) 
and VOzpeak. In a double blind, random crossover design, subjects ingested either a CHO 
(0.6g CHO/kg fat free mass (FFM) of a 20% maltodextrin solution) or placebo (PLA) 
drink each hour. Subjects completed ten, 60 minute bouts of exercise at 70% VT (46±6 
and 45±7% VOzpeak for the C and TM, respectively). Each 60 minute bout consisted of 9 
minutes of arm ergometer (double poling), 19 minutes of C, 20 minutes o f TM, followed 
by a 10-minute rest and feeding period. A standardized lunch was provided (5.46 g/kg 
FFM CHO, and 1.31 g/kg FFM protein) during both trials after the fifth hour. Muscle 
biopsies were obtained pre- and post-exercise from the vastus lateralis, and metabolic 
gases were collected every other hour during TM exercise. Blood glucose was 
continuously measured throughout the day with an indwelling glucose sensor, and total 
urine void was collected. RESULTS: Average whole body CHO oxidation on the TM 
was significantly higher during the CHO trial (269.1±64.1g) compared to PLA 
(209.6±45.8g, p=0.0012). Rates o f muscle glycogenolysis were also significantly lower 
during the CHO trial (2.5±1.8 and 5.4i2.2 g/kg wet wt./hr, for CHO and PLA 
respectively, p=0.048). Blood glucose and RPE were similar for both trials. Total 
urinary nitrogen was also similar for both trials (525.2±455.3 and 617.7±508.2 mg/dl, for 
CHO and PLA respectively, p= 0.1417). CONCLUSION: These data indicate regular 
CHO feedings can maintain whole body CHO oxidation while decreasing rates o f muscle 
glycogenolysis during 10 hours of moderate intensity intermittent exercise in females.
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Chapter One: Introduction 
Why supplement with Carbohydrate (CHO)
The intake of CHO throughout exercise can assist in maintaining blood plasma 
levels, improving performance, increasing availability of muscle substrate. Carbohydrate 
ingestion throughout exercise can be beneficial in maintaining blood glucose and insulin 
levels (Bailey et al., 2000, Campbell et al., 2001, Davis et al., 1997, Lavoie 1986). The 
ingestion o f carbohydrate during two hours o f cycling at 70% VOzmax improved time trial 
performance (Campbell et al., 2001, Carter et al., 2004). Female subjects were able to 
prolong time to fatigue during moderate to high intensity intermittent exercise when they 
were fed a 6% carbohydrate solution (Bailey et al., 2000, Davis et al., 1997, Welsh et al.
2002). Endogenous stores o f CHO are limited, so an exogenous CHO solution can be 
used during exercise as an alternate source o f energy to increase performance and 
prolong time to fatigue (Coggan and Coyle, 1991). Supplementing with CHO during 
exercise may be necessary to maintain carbohydrate oxidation (Coyle 1992).
Role of CHO on muscle and liver glycogen use
Research has addressed the topic of whether muscle glycogen was preserved 
when subjects were fed carbohydrate. However, whether exogenous CHO can reduce 
rates o f muscle glycogenolysis remains inconclusive. Female subjects were able to 
decrease hepatic blood glucose production when they were fed a 6% glucose solution 
(Campbell et al., 2001). Selz et al. (2003) and Jeukendrup et al. (1999) have 
demonstrated that exogenous CHO ingestion can reduce and shut down hepatic 
glycogenolysis in male subjects. Where some studies demonstrate a reduction in muscle
1
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glycogen oxidation when exogenous CHO is provided (Coyle and Coggan 1984), others 
maintain that exogenous CHO ingestion simply provides supplemental muscle fuel 
without altering muscle glycogen use (Coyle 1992, Jeukendrup et al., 1999). However, 
the majority o f this research has been conducted using male subjects. In contrast, Riddell 
et al. (2003) concluded that endogenous carbohydrate (muscle and liver glycogen) may 
be spared in the later stages o f prolonged exercise (at least 60 minutes) when exogenous 
carbohydrate was provided to females.
Effects on maintenance of work output
Some studies have shown that work output has been maintained with the ingestion 
o f CHO. Female subjects were able to prolong time to exhaustion by 30 minutes when 
they were fed a 6% CHO solution during exercise at 70%VO2max (Bailey et al., 2000).
Relative contribution from exogenous sources
Carbohydrate ingestion has varied from 6-8 % during exercise (Bailey et al.,
2000, Carter et al., 2004, Davis et al., 1997, and Riddle et al., 2003), but sometimes 
exogenous tracers such as '^C and [6,6-2H] glucose have been used. Tracers are utilized 
to examine the breakdown of endogenous fuel (Selz et al., 2003) and substrate utilization 
(Campbell et al., 2001, Ruby et al., 2001, Zderic et al., 2001).
Gender differences & use of females
The effects of exogenous CHO supplementation on female subjects have not been 
well documented. Previous research has suggested that females may depend more on
2
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lipid metabolism during exercise, while preserving muscle glycogen (Horton et al., 1998, 
Tamopolsky et al., 1990, 1995, 2000) compared to similarly trained males. Our lab has 
further determined that rate o f glucose appearance (Ra), disappearance (Rd) and total 
carbohydrate oxidation are lower during the luteal phase (Zderic et al., 2001) and that the 
relative contribution o f blood glucose to total carbohydrate oxidation is higher in females 
during moderate intensity exercise near the lactate threshold (Ruby et al., 2002).
Most o f the published information on carbohydrate feeding during long durational 
exercise has been performed on male subjects. Male subjects use similar substrates 
constantly while at rest, unlike females, who utilize different substrates across the 
menstrual cycle. During exercise at the same intensity, males tend to rely on 
carbohydrates and muscle glycogen, while females depend more on fat metabolism and 
muscle glycogen. Females were fed an 8% carbohydrate solution while cycling at 60% 
V02max for 90 minutcs, and contributed more exogenous CHO to overall total energy, 
compared to male subjects (14.3% and 11.2%, respectively) (Riddell et al., 2003) (Figure 
1).
CHO specific studies in females
Female subjects experienced two times the amount o f plasma glucose oxidation 
(compared to males), in relation to total energy, when they were fed exogenous CHO 
(Jeukendrup et al., 1999, and McConell et al,, 1994). Relative rates of exogenous CHO 
oxidation may also be higher in female subjects, compared to males, as demonstrated by 
the higher overall rates o f glucose oxidation. The ingestion o f glucose during exercise
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
minimizes the difference in substrate utilization and exercise performance throughout the 
menstrual cycle (Campbell et al., 2001).
Problem
The purpose o f this study was to determine the effects of exogenous carbohydrate 
ingestion on muscle fuel utilization during ten hours of moderate intermittent exercise in 
recreationally active females.
Rationale for the Study
The participation o f female athletes in ultra endurance events and in arduous 
occupational stress has grown throughout the years. The need to research female subjects 
may be o f importance because o f their increase in relative dependency on blood glucose 
(to total carbohydrate oxidation). Carbohydrate supplementation throughout long 
durational activity may help maintain blood glucose levels. Carbohydrate and other 
feeding strategies need to be addressed for the ultra endurance population.
Research Hypotheses
Hypothesis One
We hypothesized that there would be a significant decrease in the rate of muscle 
glycogenolysis when fed CHO across 10-hours of discontinuous moderate exercise.
Justification
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Research has discovered how females utilize more exogenous CHO as a fuel source 
while cycling for 90 minutes (Riddell et al., 2003) compared to males. Therefore, if  
exogenous CHO is provided throughout exercise, the rate o f muscle glycogenolysis may 
be reduced.
Hypothesis Two
We hypothesized that whole body carbohydrate oxidation would be maintained when fed 
CHO across 10-hours o f discontinuous moderate exercise.
Justification
In other studies, male subjects have shown the ability to maintain CHO oxidation when 
they were fed CHO during exercise (Hargreaves et al., 1984; Jeukendrup et al., 1999), but 
it is unknown what will happen with female subjects.
Females have demonstrated a dependence on lipid metabolism, while at the same time 
sparing muscle glycogen when not supplied with CHO (Horton et al. 1998, Tamopolsky 
et al. 1990, 1995, 2000). Therefore if  female subjects were given a CHO solution during 
exercise their fuel selection would swing from fat to CHO oxidation.
Hypothesis Three
We hypothesized that blood glucose would be maintained when fed CHO across 10-hours 
o f discontinuous moderate exercise.
Justification
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When females were supplied with a glucose infusion multiple times throughout the 
menstrual cycle and they were able to decrease the difference in blood glucose values 
between the menstrual phases (Campbell et al., 2001). Coyle (1992) concluded that 
supplying carbohydrate throughout exercise maintained blood glucose concentrations and 
CHO oxidation.
Limitations
i/ Subjects. The information gained from this investigation will only pertain to female 
subjects and not be related to males.
ii/ Exercise intensity. Subjects exercised at 70% VT throughout the ten hours, so the 
results can only be applied to individuals exercising at the same intensity.
iii/ Instrumentation. There is some error associated with all instrumentation, however, 
error will be downsized by utilizing calibrated equipment and trained laboratory 
technicians.
Delimitations
i/ Age o f subjects. Due to the study taking place on the University of Montana campus 
we were able to recruit college age subjects. We were able to control the ages o f our 
subjects (18-27 yrs.).
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ii/ Intensity levels. This investigation will only study one specific level of exercise 
intensity. This intensity was chosen because it represents the intensity o f ultra endurance 
athletes.
iii/ Menstrual status. This project will only recruit eumenorrheic females for subjects. 
Since the trials will take place in the follicular phase of the menstrual cycle, females with 
an amenorrheic cycle will be excluded.
iv/ Intermittent nature o f exercise. Throughout the ten hours of exercise subjects rotated 
activities, from beginning with arm work, and then completing each hour with leg work. 
A similar rotation in upper and lower body tasks can be seen in wildfire suppression and 
military operations.
Definition of Terms
Carbohydrate Oxidation. The amount of endogenous and exogenous CHO utilized. 
Endogenous Carbohydrate. CHO fuel sources found within the body (liver/ muscle/ 
blood).
Exogenous Carbohydrate. CHO fuel sources found outside the body (liquid/ solid CHO 
supplement).
Fat Free Mass (FFM). All non-adipose tissue.
Follicular and Luteal Phase. The follicular phase refers to the part of the menstrual 
cycle when an egg begins to mature, while the circulation of estrogen and progesterone
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
are minimal. The luteal phase refers to the part of the menstrual cycle when the 
endometrium develops and the concentration o f estradiol and progesterone are elevated. 
Glucose Ra and Rd. The rate o f appearance and disappearance o f glucose into and out of 
the blood stream.
Glycogenolysis. The breakdown o f muscle or liver glycogen to form glucose molecules. 
Lactate. The bi-product of glycolysis. Lactate production increases with an increase in 
demand for CHO fuel.
Maltodextrin. An exogenous CHO fuel source.
Muscle Glycogen. An endogenous CHO fuel source, composed of glucose molecules. 
Plasma Glucose. The amount of glucose within the plasma.
Respiratory Exchange Ratio (R£R). The ratio VCO2  expired to VO2  consumed.
During submaximal exercise, RER can be used to asses the oxidation of carbohydrates 
and fats. A RER of 0.71 indicates almost 100% fat oxidation and an RER of 1.00 
indicates about 100% CHO oxidation.
Urinary Nitrogen. The chemical marker for protein metabolism.
Ventilatory Threshold. The point where there is a rise in VO2  with out a rise in VCO2 . 
VOzmax. The maximal amount o f oxygen an individual can consume.
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Chapter Two: Review of the Literature
History o f carbohydrate as an ergogenic aid during exercise
Carbohydrate feeding has been helpful during moderate and intense exercise, as 
well as intermittent and continuous exercise in both males and females. Few studies have 
been done examining the effects o f carbohydrate feeding in females while exercise for 
long durations. The research that has been done has revealed that carbohydrate feeding 
can prolong time to fatigue (Bailey et al., 2000) during a time trial (Carter et al., 2004, 
Davis et al., 1997), decreased RPE in the legs (Davis et al., 1997), increased plasma 
glucose and insulin (Davis et al., 1997), and spared endogenous fuel sources in females 
(Riddell et al., 2003).
Carbohydrate feeding in females
When female subjects were fed 0.3 g carbohydrate per kilogram (kg) of body 
weight per 30 minutes (0.6 g CHO kg/hr), they were able to increase their time to fatigue 
while cycling at 70% VOzmax (Bailey et al., 2000) when compared to a placebo.
In a recent study, the research concluded that females may benefit from the 
ingestion exogenous carbohydrate during endurance exercise because it may spare 
endogenous fuel sources (Riddell et al., 2003). Figure 1 shows the difference in fuel 
selection when female subjects were and were not provided with carbohydrate 
supplementation during exercise. Females were able to decrease the contribution of 
endogenous fuel during the last 60 minutes of exercise when they were supplemented 
with an exogenous CHO (GLUex) (trial D). Male and female subjects were able to spare
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
endogenous fuels when given CHO, but females were able to use more exogenous CHO, 
14.3±L2% compared to 11.2±1.2% male subjects (Riddell et al., 2003).
100%
ID protein
iGLUex 
□CHOendo
Figure 1. Average percent energy contribution from protein, fat, endogenous CHO 
(CHOendo), and exogenous CHO (GLUex) in males and females during the last 60 
minutes of exercise in the PLA and CHO trials. A-male PLA, B-male CHO, C-female 
PLA, D-female CHO (Riddell et al. 2003).
Campbell et al. (2001) concluded that there were differences in performance 
across the menstrual cycle, but the differences were minimized with the ingestion of 
glucose. Subjects exercised for 2 hours at 70% VOimax and then completed a time trial 
during the follicular and luteal phases. The subjects were asked to drink a 6% solution 
containing 0.75 pCi of [6-^H] glucose before the onset o f exercise and during the glucose 
trials. Subjects completed the time trial 13% faster during the follicular control trial than 
luteal control trial. Time trial performance improved during both glucose trials, and no 
significant difference was seen between phases.
10
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A recent study examined the effect o f a five sec carbohydrate mouth rinse (6.4% 
maltodextrin solution) on time trial performance (Carter et al., 2004). Subjects were 
asked to perform a certain amount of work (914±40kJ) as fast as possible on a cycle 
ergometer, and improved time trial performance by 2.9% with the carbohydrate mouth 
rinse compared to the placebo.
Gender differences in carbohydrate metabolism and oxidation o f exogenous 
carbohydrate
Male and female subjects were asked to perform two exercise trials on the cycle 
ergometer at 60% VOipeak. During the trials, subjects ingested either an 8% carbohydrate 
solution (1 gram glucose kg-h’*) enriched with U-13C glucose or an artificially 
sweetened placebo drink. Female subjects were tested during the mid follicular phase 
and depended more on fat oxidation during the placebo trial. When subjects were fed 
exogenous carbohydrate during exercise, researchers examined the ratio o f 13C:12C in 
expired gas proportion of energy derived from exogenous carbohydrate relative to lean 
body mass, and females were able to derive more energy from the exogenous 
carbohydrate than male subjects (Riddle et al., 2003).
Other research has demonstrated that both male and female subjects experience 
positive benefits from carbohydrate feeding during high intensity intermittent exercise 
(Davis et al., 1997). An exogenous carbohydrate solution was provided pre (18% 
solution) and during exercise (6% solution). Male and female subjects cycled for one 
minute at 120-130% V02peak, followed by three minutes of rest. The subjects were asked 
to repeat the intermittent exercise until fatigue. Both male and female subjects
11
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experienced benefits from the ingestion o f carbohydrate during exercise, such as 
decreased RPE in the legs, increased time trial performance, increased plasma glucose 
and insulin (Davis et al., 1997).
Hackney (1999) concluded that decreased estrogen levels (follicular phase) 
increased muscle glycogen use, and decreased lipid metabolism. Higher estrogen levels 
during the luteal phase produced a greater dependence on lipid metabolism (Zderic et al., 
2001), sparing muscle glycogen.
Initial research by Froberg and Pedersen (1984) showed that females experienced 
lower (respiratory exchange ratio) RER values and were less glycogen depleted than 
males exercising at 80% V02max- The lower RER values noted in women at the same 
relative exercise intensity (expressed as a percentage o f V 0 2 peak), suggest that females do 
depend more on fat metabolism and less on carbohydrate even at higher intensities of 
exercise. In agreement, although at low intensity of exercise, Blatchford et al. (1985) 
found that females were more efficient at using free fatty acids during walking for 90 
minutes at 35% VOamax- Blatchford et al. did not confirm the findings with muscle 
biopsies. Muscle biopsy techniques were used by Tamopolsky (1990) and colleagues 
five years later to evaluate substrate utilization in females during a 15.5km run at 65% 
V02max (follicular phase). The research found that women did depend more on fat 
metabolism than did men as shown by 25% less of a decrease in the utilization o f muscle 
glycogen post exercise (Tamopolsky et al., 1990). Romijn et al. (2000) studied 8 
endurance trained women and had them cycle at 25%, 65%, and 85% V02max for an hour 
or less and discovered women utilize the most fat at 65% V02max (Figure 2). Figure 2 
shows how females select various fuel sources at different exercise intensities.
12
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Figure 2. Maximal caloric contribution of plasma free fatty acids (FFA) and glucose and 
minimal contribution of muscle triglyceride and glycogen stores in relation to exercise 
intensity. Values represent mean value o f 8 endurance-trained women (Romijn et al. 
2000).
Exercising at moderate intensities (90% LT) females demonstrate lower glucose 
rate o f appearance and disappearance (Ra/ Rd) and an elevated whole body fat utilization 
during the luteal phase of the menstrual cycle compared to pre ovulation (Zderic et al., 
2001). During the luteal phase, the relative contribution of blood glucose to total 
carbohydrate oxidation was significantly higher for females compared to males. 
Similarly, the calculated relative contribution from muscle glycogen was lower in 
females (Ruby et al., 2002). Tracy Horton et al. (1998) found females tend to rely more 
on fat metabolism (by examining the oxidation data as a percentage of total energy 
expenditure) than males while cycling for 2 hours at a moderately light intensity.
13
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Blood glucose levels were elevated during the luteal phase of the menstrual cycle 
during 90 minutes of exercise at 50% V02max (Horton et al., 2001). Similar results were 
noted by Ruby et al. (2002) when females exercised at 70% and 90% lactate threshold 
(LT) (39.2±2.9% VOipeak, 50.4±3.6% VOipeak, respectively) during the luteal phase with 
blood glucose contributing 35-40% more to carbohydrate fuel sources compared to 
males.
Exercise design and extended exercise
Studies have examined the effects of low, moderate, and high intensity exercise 
on females, but research has been limited on exercise duration. Previous researchers 
have reported on muscle glycogen and fuel selection in females during exercise up to 3 
hours in length, but data for exercise durations exceeding 3 hours has not been collected 
to our knowledge. Females exercising at a moderate intensity have been examined 
(Blatchford et al., 1985, Horton et al., 2002, Riddell et al., 2003, Ruby et al., 2002, Sub et 
al., 2002, Tamopolsky et al., 1990, and Zderic et al., 2001), but exercise duration was 
limited at 101 minutes. In order to assist ultra endurance athletes, wildland firefighters, 
and military operators, who are active for 8-14 hours per day, more research needs to be 
done to determine the effects o f extended muscle work.
SUMMARY
There has been an increasing amount o f research done on females during exercise, 
but there is limited research on how females response to carbohydrate feeding during 
exercise. Researchers have looked at how females respond to exercise at a variety of
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
intensities, but there has been little done on long duration exercise. Short duration 
exercise studies have proposed that females depend more on fat oxidation than CHO 
oxidation (Froberg and Pedersen 1984, Horton et al., 1998, Tamopolsky et al., 1990, 
1995, 2000, and Zderic et al. 2001;). Some studies have shown that females spare muscle 
glycogen (Froberg and Pedersen 1984, Horton et al., 1998, and Tamopolsky et al., 1990, 
1995, 2000) and demonstrate a higher dependency on blood glucose, relative to total 
energy expenditure, as a CHO fuel source (Ruby et al., 2002). Female subjects utilize a 
higher percentage o f exogenous CHO, relative to total energy expenditure (Riddell et al.,
2003). Strenuous labor scenarios like, wildland fire suppression or military assignments 
require females to work 8-14 hours per work shift, expending in upwards o f 6,000 
kilocalories per day (Ruby et al., 2002). Researchers have not yet addressed the topic of 
carbohydrate feeding during long duration exercise in females.
15
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Chapter Three: Methodology
Setting
All physiological testing took place in the Human Performance Laboratory, 
McGill Hall #112, The University of Montana.
Subjects
Six healthy, moderately trained females (age 22.8±3.1, V02peak=49.7±7.8ml*kg* 
*-min‘*), volunteered to participate in the study. All procedures were approved by the 
University o f Montana Institutional Review Board (IRB) and subjects signed an IRB 
approved informed consent form. All subjects were eumenorrheic, and not using oral 
contraceptives. Subject characteristics are shown in Table 1. All pre-trial descriptive 
measures were completed without regard to the menstrual cycle. However, the 10-hour 
trials were only conducted during the follicular phase (1-4 days post menses) of the 
menstrual cycle. Subjects were asked to maintain their normal exercise and dietary 
routines during the menstrual cycle between trials.
Preliminary Measurements
At least a week prior to the first 10-hour trial, subjects reported to the Laboratory 
on two separate occasions. They arrived the first time in an overnight fasted state to for 
the measurement of body composition. Net underwater weight was determined using an 
electronic calibrated scale (Exertech, Dresbach, MN). Body density was calculated using 
estimated residual volume (Goldman and Becklake 1959) and assuming a 0.1 gm constant
16
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for G.I. gas. Percent body fat was estimated from body density using the Lohman 
equation for females (Lohman, 1992).
Graded exercise tests (GXT) were used to determine peak oxygen consumption 
(V02peak) and ventilatory threshold (VT) on two separate days on a Quinton Q65 
treadmill (Quinton, Seattle, WA) (TM), and an electronically braked Cardgirus cycle 
ergometer (Cardgirus, Spain) (cycle). The treadmill test consisted o f a continuous 
walking protocol initiated 4.0mph (107.2 m-min"'). The grade started at 0% and 
increased 1% every 30 sec until the subject reached a respiratory exchange ratio (RER) of 
1.0. Thereafter, the percent grade was maintained, and the speed was increased to 5.0 
mph (134 m min '), and progressed 0.5 mph (13.4 m min'*) every 30 sec until volitional 
exhaustion. The cycle ergometer GXT included a 40 watt ramped protocol to volitional 
exhaustion or when a cadence above 50 revolutions per minute (rpm) could not be 
maintained.
Metabolic data were collected continuously using 15 sec averages on a calibrated 
FarvoMedics metabolic cart (ParvoMedics, Salt Lake City, UT). Ventilatory threshold 
(VT) on the TM and cycle was estimated using V-slope, excess CO2 , and ventilatory 
equivalents according to previously established methods (Gaskill et al., 2001). Exercise 
intensity for the trials was set at 70% of the mode specific VT, which represented 
43.2±6.3 and 45.7±5.6% VOzpeak for the C and TM, respectively.
During one of the initial visits, each subject familiarized themselves with the arm 
ergometer (AE) (Ergometrx, St. Paul MN) simulating the double pole motion of cross­
country skiing. The subjects determined a challenging resistance for arm portion of the 
10-hour trials.
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10-Hour Experimental and Placebo Trials
Each subject completed two 10-hour exercise trials (CHO and Placebo) in a 
randomized, double-blind, counterbalanced order. To ensure that subjects were 
beginning each trial without being glycogen depleted diet was controlled 24 hours prior 
to each 10-hour trial. Subjects consumed 5.46 g kg ' FFM of CHO and 1.31 g kg ' FFM 
of protein (PRO) throughout the control day with a third of each at each meal. For 
example, for a 55 kg FFM subject, 300.3 g CHO and 72.1 g protein were consumed per 
day (100.1 g CHO and 24 g protein per meal). Although the amount of fat provided was 
not standardized across the subjects, each pre 10-hour trial day was eucaloric within each 
subject. Dietary analyses were completed using the Food Processor program (ESHA). 
Subjects were allowed to add to the diet before the first trial, as long as the same diet was 
followed during the day before the second trial.
For each 10-hour trial subjects reported to the Laboratory at 5:30am, following an 
overnight fast. The glucose sensor (Medtronic Minimed, Northridge, CA) was implanted 
above the gluteus maximus as soon as the subject arrived. A One Touch Ultra 
glucometer (Milpitas, CA) was used to compare pre-exercise, pre-lunch, and post- 
exercise time points and to calibrate the indwelling glucose sensor.
A pre exercise muscle biopsy was obtained from the vastus lateralis. The biopsy 
was performed with the subject in the supine position. Local anesthesia (2% lidocaine) 
was used prior to making a 3-5 mm incision approximately 12-16 cm laterally above the 
patella. Each biopsy yielded approximately 40-60mg o f muscle using a Bergstrom 
biopsy needle with suction. Visible blood and connective tissue were immediately
18
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removed from the muscle sample before storing in liquid nitrogen. Samples were 
immediately frozen in liquid nitrogen and stored at -80°C until the glycogen assay was 
measured in triplicate (Melanson et al., 2002).
Following the biopsy, subjects were encouraged to void their bladder and bowel if 
possible and a pre-exercise weight was recorded. Subjects were provided with a small 
standardized breakfast consisting o f apple juice, a bagel, and an energy bar (1.82 g CHO 
kg'^ FFM and 0.44 g protein kg'^ FFM per meal. Time was recorded between the end of 
breakfast and the onset o f exercise. The average time between the completion of 
breakfast and the onset o f exercise was 23.3±9.6 and 17.9±5.8 min for the PLA and 
CHO, respectively (p>0.05). Each 10 hour trial began once breakfast was finished and a 
5ml blood sample (5ml) was obtained from an anticubital arm vein. Additional blood 
samples were obtained after the completion of hour five (pre-lunch) and immediately 
post-exercise.
Subjects completed the each 10-hour trials which consisted of 9 minutes o f AE, 1 
minute transition, 19 minutes of cycle, 1 minute transition, 20 minutes of TM, and 10 
minutes o f rest and liquid feeding. During each rest period, subjects received the liquid 
CHO or PLA drink. Both the PLA and CHO drinks were equal in volume and similarly 
colored and flavored. The CHO drink consisted of a commercially available 20% 
solution (Gatorade Sport Science Institute, Barrington, IL), and the subjects received 
0.6g/kg FFM at each rest break, except at hours 5 (lunch) and 10 (end of trial).
A 40 minute lunch break was provided between hours 5 and 6. Lunch consisted 
o f a small sandwich including mozzarella cheese, iceberg lettuce and mayonnaise on
19
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wheat bread, apple sauce, and an energy food bar providing 1.82 g CHO and 0.44 g 
protein per meal.
Metabolic gases were periodically collected on both the cycle and the TM. Gas 
collection occurred on the cycle only during the first hour of trial one to ensure accurate 
workload selection (70% of VT). Additional metabolic gas collections were conducted 
during the last five minutes on the TM during hours 1,3,5,6,8, and 10 using the same 
metabolic system as described above. Prior to each gas collection, the metabolic system 
was calibrated with a 3-liter calibration syringe and medical gases of known 
concentrations (16.6 % O2 , 4.37% CO2  N 2  balance). The subjects maintained a constant 
workload for each mode of exercise throughout both of the 10-hour trials.
Heart rates were monitored using a Polar heart rate monitor (Polar, Port 
Washington, NY) during the last five minutes of each session on the cycle and the TM 
each hour during both exercise trials.
Immediately upon completion o f the 10* hour o f exercise, the post-exercise blood 
sample was obtained (Figure 3). The subject was then instructed to void and a post 
exercise weight was obtained. The post muscle biopsy was taken approximately 2 cm 
proximal to the pre-exercise biopsy about 20 minutes post-exercise (21.4±2.6 and 
19.7±3.0 minutes for the PLA and CHO trials, respectively), and handled as described 
above.
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Figure 3. 10-Hour timeline for the PLA and CHO trials. The timeline begins with the 
subjects arriving to the lab and terminates with the completion of trial 1 0  and the muscle 
biopsy.
Whole Body Substrate Oxidation
Whole body fat and CHO oxidation were estimated using steady state VO2  and 
VCO2  data (Frayn, 1983) from the last 2.5 minutes o f metabolic gas collection for hours
1,3,5,6,8, and 10 on the TM.
CHO (g/min) = (4.55 X VCO2 ) -  (3.21 x  VO2 )
Fat (g/m in) = (1.67 X VO2 ) -  (1.67 x VCO2 )
VO2  and VCO2  are in L/min.
Assays
The glucose, lactate, and insulin assays were done in duplicate, and glycogen was 
measured in triplicate from the same muscle sample (approximately 15-25mg). The 
glucose and lactate concentrations from the 1 0 -hour trials were analyzed with an 
enzymatic assay (Infinity Glucose, Thermo Electron Corporation) using a 
spectrophotometer, (Spectronic 401, Milton Roy). Insulin was measured with 
commercially available Elisa assay (DRG, EIA-2935, Marburg, Germany).
Muscle glycogen was analyzed using a similar enzymatic spectrophotometric 
method (Infinity glucose (HK) liquid stable reagent, ThermoTrace Ltd.) after tissue 
preparation. Samples (22.6 ± 1.7 mg wet weight) were weighed upon removal from a -  
80° C freezer. Samples were placed in 1 ml, 1 N HCL solution and homogenized using a 
manual mortar and pestle tissue grinder. Once homogenized, samples were incubated at
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95.6° C for three hours. After the incubation, 0.5ml, 1 N NaOH was added to 0.5ml of 
boiled tissue sample to normalize pH. Samples were analyzed in triplicate against known 
glycogen and glucose controls run at the same time. Muscle glycogen was expressed in 
mmol kg'^ wet weight of muscle.
Statistics
Glycogen, glycogen depletion rate (per hour) and body weight were examined 
using a 2x2 repeated measures ANOVA (trial: [CHO vs. placebo], and time: [pre vs. 
post]). Carbohydrate and fat oxidation were analyzed using a 2x6 ANOVA (trial: [CHO 
vs. placebo], and time: [1, 3, 5, 6 , 8 , and 10 hour]). Blood glucose (from the indwelling 
glucose sensor) was analyzed with a 2x10 repeated measures ANOVA (trial: [CHO vs. 
placebo], and time: [hourly 1-10]. Average HR on the cycle ergometer and treadmill, and 
average watts on the UBE were analyzed using a 2x10 ANOVA (trial: [CHO vs. 
placebo], and time: [hourly 1-10]). Total daily nitrogen concentration was examined 
between the CHO and placebo trials using a dependent t-test across trials. Statistical 
significance was established at p<0.05.
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Abstract
PURPOSE: To determine the effects of CHO feeding during 10-hours of moderate 
exercise on muscle glycogen and substrate utilization in females. METHODS: Six 
moderately trained females (age 23±3 yr, eumenorrheic and not taking oral 
contraceptives) completed a double blind, random crossover design protocol. Subjects 
ingesting either a CHO (0.6g CHO/kg fat free mass (FFM) of a 20% maltodextrin 
solution) or placebo (PLA) drink each hour for 10 hours of exercise. Each hour included 
9 minutes on an arm ergometer, 19 minutes on a cycle ergometer (CE) and 20 minutes on 
a treadmill (TM), each at 70% of mode specific ventilatory threshold (VT) with 10- 
minute rest and feeding. A standardized lunch was provided (5.5 g/kg FFM CHO, and 
1.3 g/kg FFM protein) during both trials after the fifth hour. Muscle biopsies were 
obtained pre- and post-exercise from the vastus lateralis, and metabolic gases were 
collected every other hour on the TM. Blood glucose was continuously measured with an 
indwelling glucose sensor, and total urine void was collected. RESULTS: Whole body 
CHO oxidation was significantly higher during the CHO trial (269.1±64.1g) compared to 
PLA (209.6±45.8g, p<0.01). Rates of muscle glycogenolysis were about 50% lower 
during the CHO trial (2.5±1 . 8  vs. 5.4±2.2 mmol/kg wet wt./hr, p<0.05). Blood glucose 
was not different across trials. Total urinary nitrogen was also similar for both trials 
(525.2 ± 455.3 and 617.7 ± 508.2 mg/dl, for CHO and PLA respectively, p>0.05). 
CONCLUSION: These data indicate that regular CHO feedings maintain whole body 
CHO oxidation and markedly reduces muscle glycogenolysis during 10 hours of 
moderate intensity intermittent exercise in females.
Key Words: Carbohydrate feeding. Females, Carbohydrate oxidation, Muscle 
glycogenolysis. Glycogen
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INTRODUCTION 
Paragraph 1
Although, the inclusion of female subjects has increased during applied exercise 
studies, the responses to carbohydrate (CHO) feeding during extended exercise has not 
received adequate attention. Past research has described the physiological responses to 
exercise at a variety o f intensities during short duration activity, but little has been 
reported on long duration exercise. During exercise trials ranging from 60-120 minutes, 
it has been demonstrated that the relative contribution from fat sources is higher in 
females compared to similarly trained males under fasted conditions (Froberg and 
Pedersen 1984; Horton et al. 1998; Tamopolsky et al. 1990, 1995, 2000). It also appears 
that females are less reliant on muscle glycogen compared to males in the fasted state 
(Froberg and Pedersen 1984; Horton et al. 1998; Tamopolsky et al. 1990, 1995, 2000) or 
when fed an exogenous CHO (Riddell et al. 2003). Similarly, our laboratory has 
demonstrated that the relative contribution of muscle glycogen to total CHO oxidation is 
significantly lower in females during exercise near the lactate threshold (Ruby et al. 
2001).
Paragraph 2
It appears that there is general consensus in the literature that regular CHO 
feedings provide an ergogenic benefit during extended moderate and intense exercise, as 
well as intermittent and continuous exercise in both males and females. However, few 
studies have determined the ergogenic benefit o f CHO feeding in females while 
exercising for long durations. Regardless, past research has demonstrate that CHO
26
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feeding can prolong time to fatigue (Bailey et al. 2000), improve time trial performance 
(Carter et al. 2004, Davis et al. 1997), decrease RPE in the legs (Davis et al. 1997), and 
increased plasma glucose and insulin (Davis et al. 1997).
Paragraph 3
Although the ergogenic effects o f regular CHO feeding strategies have been 
generally successful during exercise durations up to 1 2 0  minutes, other occupations and 
athletic events required extended muscle work under arduous conditions (military 
operations, wildfire suppression, mining, construction jobs, ultra endurance running and 
triathlon events). These labor and/or competitive scenarios require females to work 8-14 
hours at a time, often requiring an energy expenditure in upwards of 6 , 0 0 0  kcal or 
21MJ day'* (Ruby et al. 2002). Currently, the effects o f CHO feeding during extended 
physical work in the female has received little or no attention. The purpose o f our study 
was to determine the effects o f CHO feeding on muscle glycogenolysis and whole body 
substrate oxidation during 1 0 -hours of intermittent moderate intensity exercise in 
recreationally active females. We hypothesized that regular CHO feeding would 
decrease rates o f muscle glycogenolysis while maintaining blood glucose and whole body 
CHO oxidation.
METHODOLOGY 
Subjects 
Paragraph 4
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Six healthy, moderately trained females served as subjects. All procedures were 
approved by the University Institutional Review Board (IRB) and subjects signed an IRB 
approved informed consent form. All subjects were eumenorrheic, and not using oral 
contraceptives. Subject characteristics are shown in Table 1. All pre-trial descriptive 
measures were completed without regard to the menstrual cycle. However, the 10-hour 
trials were only conducted during the follicular phase (1-4 days post menses) of the 
menstrual cycle. Subjects were asked to maintain their normal exercise and dietary 
routines during the menstrual cycle between trials.
Preliminary Measurements 
Paragraph 5
At least a week prior to the first 10-hour trial, subjects reported to the Laboratory 
on two separate occasions. They arrived the first time in an overnight fasted state for the 
measurement of body composition. Net underwater weight was determined using an 
electronic calibrated scale (Exertech, Dresbach, MN). Body density was calculated using 
estimated residual volume (Goldman and Becklake 1959) and assuming a 0.1kg constant 
for G.L gas. Percent body fat was estimated from body density using the Lohman 
equation for females (Lohman, 1992).
Paragraph 6
Graded exercise tests (GXT) were used to determine peak oxygen consumption 
(VOzpeak) and VO2  at the ventilatory threshold (VOivr) on two separate days on a Quinton 
Q65 treadmill (Quinton, Seattle, WA) (TM), and an electronically braked cycle
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ergometer (Cardgirus, Spain) (cycle). The treadmill test consisted o f a continuous 
walking protocol initiated at 107.2 m min"% 0% grade and progressed by 1% grade every 
30 seconds thereafter until reaching a respiratory exchange ratio (RER) of 1.0. 
Thereafter, the percent grade was maintained, while the speed was increased to 134 
m min'* and progressed 13.4 m min‘* every 30 seconds until volitional exhaustion. The 
cycle ergometer test included a 40 watt ramped protocol starting at 0 watts to volitional 
exhaustion or when a cadence above 50 revolutions per minute (rpm) could not be 
maintained.
Paragraph 7
Metabolic data were collected continuously using 15 sec averages on a calibrated 
ParvoMedics metabolic cart (ParvoMedics, Salt Lake City, UT). Treadmill and cycle 
VOivT was estimated using V-slope, excess CO2 , and ventilatory equivalents according 
to previously established methods (Gaskill et al., 2001). Exercise intensity for the trials 
was set at 70% of the mode specific VOzvr, which represented 43.2±6.3 and 45.7±5.6% 
V 0 2 peak for the cycle and TM, respectively.
Paragraph 8
During one o f the initial visits, each subject familiarized themselves with the arm 
ergometer (AE) (Ergometrx, St. Paul MN) simulating the double pole motion of cross­
country skiing. The subjects determined a challenging resistance for the arm portion of 
the 1 0 -hour trials.
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10-Hour Experimental and Placebo Trials 
Paragraph 9
Each subject completed two 10-hour exercise trials (CHO and Placebo) in a 
randomized, double-blind, counterbalanced order. To ensure that subjects were 
beginning each trial without being glycogen depleted, diet was controlled 24 hours prior 
to each 10-hour trial. Subjects consumed 5.46 g/kg FFM of CHO and 1.31 g/kg FFM of 
protein (PRO) throughout the control day with a third of each at each meal. For example; 
for a 55 kg FFM subject, 300.3 g CHO and 72.1 g protein were consumed per day (100.1 
g CHO and 24 g protein per meal). Although the amount of fat provided was not 
standardized across the subjects, each pre 1 0 -hour trial day was eucaloric for all 
macronutrients within each subject. Dietary analyses were completed using the Food 
Processor program (ESHA). Subjects were allowed to add to the diet before the first 
trial, as long as the same diet was followed during the day before the second trial. For 
each 10-hour trial subjects reported to the Laboratory at 5:30am, following an overnight 
fast. The glucose sensor (Medtronic Minimed, Northridge, CA) was implanted above the 
gluteus maximus as soon as the subject arrived. A One Touch Ultra glucometer 
(Milpitas, CA) was used to compare pre-exercise, pre-lunch, and post-exercise time 
points and to calibrate the indwelling glucose sensor.
Paragraph 10
A pre exercise muscle biopsy was obtained from the vastus lateralis. The biopsy 
was performed with the subject in the supine position. Local anesthesia (2% lidocaine) 
was used prior to making a 3-5 mm incision approximately 12-16 cm laterally above the
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patella. Each biopsy yielded approximately 40-60mg o f muscle using a Bergstrom 
biopsy needle with suction. Visible blood and connective tissue were immediately 
removed from the muscle sample before storing in liquid nitrogen. Samples were stored 
at -80°C until the glycogen assay was measured in triplicate (Melanson et al., 2002).
Paragraph 11
Following the biopsy, subjects were encouraged to void their bladder and bowel if 
possible and a pre-exercise weight was recorded. Subjects were provided with a small 
standardized breakfast consisting of apple juice, a bagel, and an energy bar (1.82 g 
CHO kg'^ FFM and 0.44 g protein kg'^ FFM per meal). Time was recorded between the 
end o f breakfast and the onset o f exercise. The average time between the completion of 
breakfast and the onset o f exercise was not different for the PLA and CHO trials 
(23.3±9.6 and 17.9±5.8 min, p>0.05). Each 10 hour trial began once breakfast was 
finished and a 5ml blood sample was obtained from an anticubital arm vein. Additional 
blood samples were obtained after the completion of hour five (pre-lunch) and 
immediately post-exercise.
Paragraph 12
Each hour o f the 10-hour trial consisted o f 9 minutes of AE, 1 minute transition,
19 minutes of cycle, 1 minute transition, 20 minutes of TM, and 10 minutes of rest and 
liquid feeding. During each rest period, subjects received the liquid CHO or PLA drink. 
Both the PLA and CHO drinks were equal in volume and similarly colored and flavored. 
The CHO drink consisted o f a commercially available 20% solution (Gatorade Sport
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Science Institute, Barrington, IL), and the subjects received 0.6g kg'’ FFM at each rest 
break, except at hours 5 (lunch) and 10 (end of trial).
Paragraph 13
A 40 minute lunch break was provided between hours 5 and 6 . Lunch consisted 
o f a small sandwich (mozzarella cheese, iceberg lettuce and mayonnaise on wheat bread), 
apple sauce, and an energy food bar. The meal provided 1.82 g CHO and 0.44 g protein 
per meal.
Paragraph 14
Metabolic gases were periodically collected on both the cycle and the TM. Gas 
collection occurred on the cycle only during the first hour of the first trial to ensure 
accurate workload selection (70% of VOivr). Additional metabolic gas collections were 
conducted during the last five minutes on the TM during hours 1,3,5,6,8, and 10 using the 
same metabolic system as described above. Prior to each gas collection, the metabolic 
system was calibrated with a 3-liter calibration syringe and medical gases o f known 
concentrations (16.6 % O2 , 4.37% CO2 ,N 2  balance). The subjects maintained a constant 
workload for each mode o f exercise throughout both of the 1 0 -hour trials.
Paragraph 15
Heart rates were monitored using a Polar heart rate monitor (Polar, Port 
Washington, NY) during the last five minutes of each session on the cycle and the TM 
each hour during both exercise trials.
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Paragraph 16
Immediately upon completion o f the 10“* hour o f exercise, a post-exercise blood 
sample was obtained. The subject was then instructed to void and a post-exercise weight 
was obtained. The post muscle biopsy was taken approximately 2 cm proximal to the 
pre-exercise biopsy about 20 minutes post-exercise (21.4±2.6 and 19.7±3.0 minutes for 
the PLA and CHO trials, respectively, NS), and handled as described previously.
Whole Body Substrate Oxidation 
Paragraph 17
Whole body fat and CHO oxidation were estimated using steady state VO2  and 
VCO2  data (Frayn, 1983) from the last 2.5 minutes of metabolic gas collection for hours
1,3,5,6,8, and 10 on the TM.
Assays
Paragraph 18
The glucose, lactate, and insulin assays were done in duplicate, and glycogen was 
measured in triplicate from the same muscle sample (approximately 15-25mg). The 
glucose and lactate concentrations from the 1 0 -hour trials were analyzed with an 
enzymatic assay (Infinity Glucose, Thermo Electron Corporation) using a 
spectrophotometer, (Spectronic 401, Milton Roy). Insulin was measured with a 
commercially available Elisa assay (DRG, EIA-2935, Marburg, Germany).
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Paragraph 19
Muscle glycogen was analyzed using a similar enzymatic spectrophotometric 
method (Infinity glucose (HK) liquid stable reagent, ThermoTrace Ltd.) after tissue 
preparation. Samples (22.6 ±1 .7  mg wet weight) were weighed upon removal from a -  
80“ C freezer. Samples were placed in 1 ml, 1 N HCL solution and homogenized using a 
manual mortar and pestle tissue grinder. Once homogenized, samples were incubated at 
95.6“ C for three hours. After the incubation, 0.5ml, 1 N NaOH was added to 0.5ml of 
boiled tissue sample to normalize pH. Samples were analyzed in triplicate against known 
glycogen and glucose controls run at the same time. Muscle glycogen was expressed in 
mmol kg'^ wet weight o f muscle.
Statistics 
Paragraph 20
Pre- to post-exercise glycogen, hourly glycogen depletion rate and body weight 
were examined using a 2x2 repeated measures ANOVA (trial: [CHO vs. placebo], and 
time: [pre vs. post]). Carbohydrate and fat oxidation were analyzed using a 2x6 ANOVA 
(trial: [CHO vs. placebo], and time: [1, 3, 5, 6 , 8 , and 10 hour]). Blood glucose (from the 
indwelling glucose sensor) was analyzed with a 2x10 repeated measures ANOVA (trial: 
[CHO vs. placebo], and time: [hourly 1-10]. Average HR on the cycle ergometer and 
treadmill, and average watts on the UBE were analyzed using a 2x10 ANOVA (trial: 
[CHO vs. placebo], and time: [hourly 1-10]). Total daily nitrogen concentration was 
examined between the CHO and placebo trials using a one-way repeated measures 
ANOVA across trials. A one factor ANCOVA was used to examine the change in
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muscle glycogen pre- and post-exercise during both trials. Statistical significance was 
established at p<0.05.
RESULTS 
Subject Descriptions 
Paragraph 21
Table 1 summarizes the descriptive characteristics o f the study.
Changes in body weight (0.7±0.5kg) were not significantly different between the 
CHO and PLA trials. However the main effect for time was statistically significant 
indicating an overall reduction in body weight across the trials.
Exercise Descriptions 
Paragraph 22
Intensity of exercise remained constant throughout both trials within mode on the 
cycle and the TM and is represented in Table 2. Subjects self selected the intensity on the 
arm ergometer during both trials and were not different across trials.
Whole Body Substrate Utilization 
Paragraph 23
Overall the average RER values for the CHO trial were significantly higher than 
the placebo (0.91±0.035 and 0.86±0.025, respectively (p<0.05). When RER data were 
compared across time (Figure 4), the trial x time interaction was statistically significant 
(p<0.05). RER values were significantly reduced at hours 3, 5, 8 , and 10 during the
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placebo trial compared to the CHO trial. The RER values post meals hour land 6  were 
not different.
Paragraph 24
Whole body total CHO oxidation on the treadmill was significantly higher for the 
CHO trial (269.1±64.1 vs. 209.6±45.8g, p<0.01) compared to the PLA trial. When the 
average rates of CHO oxidation (g'miri*) were compared across time. Figure 4, the trial x 
time interaction was statistically significant (p<0.05). Overall, rates of CHO oxidation 
were unchanged during the CHO trial. In contrast, rates of CHO oxidation were 
significantly reduced at hours 3, 5, 8 , and 10 during the placebo trial compared to the 
CHO trial. The rate of CHO oxidation post meals (hours 1 and 6 ) were not different.
Paragraph 25
Whole body total fat oxidation on the treadmill was significantly higher for the 
placebo trial (68.01±14.5 vs. 43.9±16.8g, p<0.01) than the CHO trial. When the average 
rates of fat oxidation (g‘m iri‘) were compared across time (Figure 5), the trial x time 
interaction was statistically significant (p<0.05). Rates of fat oxidation were significantly 
elevated at hours 3, 5, 8 , and 10 during the placebo trial compared to the CHO trial. The 
rate o f fat oxidation post meals (hour 1  and 6 ) were not different.
HR, RPE, blood data, glycogen, urinary nitrogen 
Paragraph 26
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The trial x time interaction was not significant for the heart rate response on the 
cycle ergometer (Figure 7) or on the treadmill (Figure 8 ). However, the main effect for 
HR over time was statistically significant (p<0.05) on the cycle and TM. The average 
heart rate response on both the cycle and TM were significantly higher during the PLA 
trial compared to the CHO trial.
Paragraph 27
The trial x time interaction was not significant for the measure of RPE. However, 
the main effect for RPE across time was statistically significant (p<0.05) indicating an 
increase in RPE over the duration of the trial with RPE at hours 8  and 10 (Figure 9) 
compared to hour 1 .
Paragraph 28
The trial x time interaction for measures o f blood glucose (indwelling sensor, 
whole blood, and finger stick) were not significant. The main effect for blood glucose 
across time was not significantly different across trials (p>0.05) when using the 
indwelling sensor (Figure 10 & 11). However, the main effect for blood glucose across 
time was statistically significant (p<0 .0 1 ) for blood glucose when using whole blood and 
the finger stick (p<0.05). These data are summarized in Table 3.
Paragraph 29
The trial x time interaction for the measure o f insulin was not significant. 
However, the main effect for time was statistically significant (p<0.01) for the measure of
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insulin at hours 5 (pre-lunch) and 10 (post-exercise) when compared to pre-exercise in 
both trials (Table 3).
Paragraph 30
The time x trial interaction for the measure o f lactate was not significant. 
However, the main effect for lactate across time was statistically significant (p<0.05) at 
hours 5 (pre-lunch) and 10 (post-exercise) during the CHO trial only when compared to 
pre-exercise (Table 3).
Paragraph 31
Both 10 hour trials demonstrated a significant decrease across the 10 hours in 
muscle glycogen with the decrease during the CHO trial less than the PLA trial (PLA: A= 
-54,3±21.7 mmol/kg wet wt (p<0.01), CHO: A= -21.9±18.0 mmol/kg wet wt (p<0.05)). 
Although diet was controlled the day before each trial, the concentration o f muscle 
glycogen was significantly greater pre exercise for the PLA trial vs. CHO (180.3±31.0 vs. 
150.0±35.8 mmol kg'^ wet wt, p<0.01) (Figure 12). An ANCOVA was used to 
standardize for the difference in pre values for both trials. There was a statistically 
significant decrease between the change (A) in muscle glycogen for the CHO vs. PLA 
(p<0.05) (Figure 13). There was a 44% and 13% change in muscle glycogen pre to post 
exercise for the PLA and CHO trial respectively.
Paragraph 32
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Calculated rates o f muscle glycogenolysis (mmol kg ' wet muscle hr "') (Figure 
14) were significantly lower during the CHO trial (p< 0.05). The average rate of 
glycogen oxidation during the CHO trial was 41% of the rate during the PLA trial.
Paragraph 33
There were no significant differences in total urinary nitrogen excretion across the 
trials (525.2±455.3 vs. 617.7±508.2 mg/dl, for the CHO and PLA trials, respectively).
DISCUSSION 
Paragraph 34
The purpose o f this investigation was to determine the effects of regular CHO 
feedings on rates o f whole body CHO oxidation and muscle glycogenolysis during ten 
hours o f muscle work. Although it has been shown that liquid CHO feedings during 
exercise preserve endogenous fuel sources while increasing the oxidation of exogenous 
fuel (Riddell et al., 2003), other studies have shown that CHO ingestion does not alter 
rates o f muscle glycogenolysis (Coyle et al., 1992). Additional data has also determined 
that CHO ingestion at rate of 1.0-1.7 g min'' can suppress and even shut down liver 
glycogenolysis (Jentjens et al., 2004, Selz et al., 2003). There are reports in the literature 
indicating that females have a greater dependence on fat metabolism during exercise of 
moderate intensities compared to similarly trained males (Horton et al., 1998, Froberg 
and Pedersen 1984, Romijn et al., 2000, and Tamopolsky et al., 1990) and a decrease in 
whole body CHO oxidation (Tamopolsky et al. 1990,1995, 2000). This general 
reduction in CHO oxidation and apparent increased relative dependency on fat sources
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has been used to explain the decrease in muscle glycogenolysis across the sexes. 
However, recent research from our laboratory has demonstrated similar rates of whole 
body CHO and fat oxidation in similarly trained males and females during exercise near 
the lactate threshold. Although there were no sex differences in total CHO oxidation, the 
relative contribution of blood glucose to total carbohydrate oxidation was significantly 
higher in females (Ruby et al. 2002). The primary finding in the present investigation 
was that liquid CHO mediated about a 50% decrease in muscle glycogenolysis during 
moderate exercise compared to a 10 hour placebo trial. This clearly demonstrates a 
major glycogen sparing effect when subjects were fed exogenous CHO at an average rate 
o f 0.5 g m in '\ Similarly, this rate of exogenous feeding maintained whole body CHO 
oxidation during the CHO feeding trial. In contrast, when subjects were not provided 
with regular supplemental CHO, rates of whole body CHO oxidation were dramatically 
reduced during the later hours o f the 1 0  hour trial.
Paragraph 35
These data are in contrast to a study by Walker et al. (2000) who demonstrated an 
increase in CHO oxidation without supplemental feeding during exercise. However, 
females were fed a diet consisting o f moderate amounts of CHO (48% CHO) for three 
days, followed by a high CHO (78% CHO) diet for four days, compared to eating only a 
moderate CHO diet for seven days (Walker et al. 2000). The combination pre-load diet 
composed o f moderate and high CHO was able to increase pre-exercise muscle glycogen 
concentrations, but post-exercise (cycling to exhaustion at 8 0 %VO2 max) net glycogen 
utilization was higher during this diet versus the moderate CHO diet (Walker et al. 2000).
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However, the exercise duration in this study was only about 75 minutes and represents a 
relatively short exercise period.
Paragraph 36
A decrease in muscle glycogen utilization and an increase in blood glucose 
utilization were seen in females who ran 15.5 kilometers at 65%V02max in under 100 
minutes without CHO feeding, compared to male subjects (Tamopolsky et al., 1990). 
Similar results were seen in females during 25 minutes of exercise at 90%LT (Ruby et 
al., 2002). Although indirect estimates o f muscle glycogen were used, it was still the 
dominant contributor to total CHO oxidation in males and females, and the relative 
contribution from blood glucose was higher in the females (Ruby et al., 2002). Increased 
intensities of exercise (80% and 90% V02max) produce a greater dependency on CHO 
oxidation (Romijn et al., 2000) and an overall increase in muscle glycogenolysis (Froberg 
and Pedersen 1984). As the exercise intensity is increased, the relative contribution of 
muscle glycogen to total CHO oxidation is also increases. It should be noted that the 
average exercise intensity (70%VT) in the present investigation represents 43.2±6.3 and 
45.7±5.6 %V02max for the cycle and treadmill segments o f each hour. Considering the 
data o f Romijn et al., (2000), it can be estimated that the relative contribution o f muscle 
glycogen to total CHO oxidation approximated either 9% (when subjects were working at 
25%V02max) or 34% (when subjects were working at 65%V02max) during the early hours 
o f the exercise protocol.
Paragraph 37
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In the present investigation, the changes in blood glucose across time were similar 
for both trials with glucose values from whole blood and finger stick samples 
demonstrating a significant decrease, while the indwelling sensor showed a general 
maintenance o f blood glucose. Suh et al., 2002 studied women at rest for 90 minutes 
followed by 60 minutes o f exercise at either 45% or 65% VOimax and noted a similar 
blood glucose response for both trials. On the other hand, subjects who were fed 0.6g 
CHO per kg BW* per hour'* while cycling to exhaustion at 70% VOimax demonstrated a 
significant increase in plasma glucose during the CHO trials (Bailey et al,, 2000, Riddell 
et al., 2003). However, the exercise intensity for these studies was considerably higher 
compared to the present investigation. Therefore, the expected rate of hepatic 
glycogenolysis and the resultant glucose Ra would be considerably higher. In the present 
data, it is possible that the combination of the lower exercise intensity and the subsequent 
CHO feedings would completely suppress hepatic glucose production. Even the small 
standardized breakfast and lunch may have provided adequate CHO sources to either 
maintain hepatic glycogen or substitute for a decreased hepatic glucose production.
Also, during the current study we examined the average blood glucose values per hour 
when using the indwelling sensor. Since the values were averaged each hour this may 
have led us to conclude inappropriately. However, when the blood glucose values for the 
indwelling sensor were plotted every 5 min throughout the trials there was no difference 
in blood glucose throughout exercise.
Paragraph 38
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Over 10 hours o f exercise, there were no significant differences in average urinary 
nitrogen concentrations, an indirect indicator of protein catabolism. The large standard 
deviations demonstrate high interindividual variation in this marker, but even using a 
repeated measures design there were no differences and small intraindividual variations 
between trials. Previous research with females who consumed a high (75%) CHO diet 
before the onset of exercise demonstrated lower plasma urea concentrations after cycling 
for 60 minutes at 75% VOzmax (Tamopolsky et al., 1995) compared to low carbohydrate 
diet. From this same laboratory it has also been shown that females maintain a lower 
excretion o f urea nitrogen compared to males during a 15.5 km run at 65% VOzmax 
(Tamopolsky et al., 1990). Previous research has tested female subjects at a higher 
percent o f V O zm a x  than our current research, and this may have led Tamopolsky et al. 
(1990, 1995) to find differences in urea nitrogen concentration.
Paragraph 39
The research suggests that insulin concentrations are down regulated with the 
onset o f exercise (Suh et al., 2002). Our data showed that insulin concentration was 
reduced across time. Hackney et al., (1999) found insulin concentrations to decrease 
when exercising at 70% V O zm ax- When subjects were supplemented with CHO, insulin 
concentrations also increased compared to the PLA trial (Bailey et al., 2000, Campbell et 
al., 2001). Our research demonstrated that there were no differences in insulin 
concentrations between trials. In both the CHO and PLA trials insulin concentrations 
decreased throughout 10-hours of exercise. This decrease over time may be a function of 
the lower exercise intensity or the extended duration of the exercise or both.
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Paragraph 40
Lactate concentrations rise exponentially with an increase in exercise intensity 
(Horton et al., 1998, Froberg and Pedersen 1984, Romijn et al., 2000, Suh et al., 2002, 
Walker et al., 2000). Researchers reported a significant increase in lactate concentrations 
at 65% VOimax compared to exercise at 45% VOimax (Suh et al., 2001). Other studies 
have found a significant decrease in lactate concentrations over 90 min (Riddell et al., 
2003). In our study there were no significant differences in the absolute exercise 
intensity across trials. There was, however, significant decrease in blood lactate 
concentrations during the CHO trial compared to the PLA trial which did not change over 
time.
Paragraph 41
In this study the subjects did not demonstrate any differences in body weight pre- 
to post-trial, because 0.7kg was lost during each trial. A reason for the lack of change in 
body weight between trials was that there was no difference in hydration status. The 
subjects consumed the same amount of CHO/PLA drink (p=0.773388) and usually self 
selected the same amount o f water to drink during each trial. The average water and 
liquid supplement intake during placebo and CHO trials were 3.8±1.1 L, 3.S>±1.3 L 
respectively.
Paragraph 42
In a prior trial (Campbell et al., 2001) the researchers found no difference in HR 
between CHO and PLA trials on the cycle ergometer. The present 10-hour study is in
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agreement with the prior findings. A possible reason for the unchanged heart rate values 
during 1 0  hours of exercise could be due to the subjects equally hydrating during each 
trial. Another possible reason for the lack of difference in heart rate values across the 
trials may be due to maintaining the same exercise intensity during both trials. The 
intensity (44±5% VOzmax) may have been too low to affect heart rate, although Campbell 
et al. did not find any differences in heart rate at 70% VOzmax on the cycle ergometer. 
However, HR was different across time (see main effect in Figures 7 and 8 ).
Paragraph 43
Our research found that heart rates on the TM were not significantly lower during 
the CHO trial compared to PLA.
Paragraph 44
Our subjects’ RPE values were not significantly different after 10 hours of 
exercise between the CHO and PLA trials. However, there was a gradual main effect 
across time (hours 8  and 10 demonstrated significantly higher RPE values compared to 
hour 1). This may also be a function o f the moderate exercise intensity and/or the 
extended duration o f work. These data are in agreement with past research that also 
observed limited differences in RPE between CHO and PLA trials (Carter et al., 2004). 
However, it has also been reported that CHO feedings vs. PLA have the potential to 
reduce RPE during exercise (Utter et al., 1997, 2002, 2004) which have been shorter in 
duration (2.5 to 3.5 hours) and at higher exercise intensities (70 to 80%VO2peak)-
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Paragraph 45
In conclusion, these results indicate that exogenous CHO provided at a rate o f 0.5 
g min'^ reduces rates o f muscle glycogenolysis by 50% compared to PLA. Moreover, 
these data clearly indicate that during moderate intensity, long duration muscle work, 
exogenous CHO maintains whole body CHO oxidation but does not alter the perception 
o f effort or heart rate. Further studies should evaluate additional exercise intensities over 
extended exercise periods.
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TABLES and FIGURES
Table 1. Subject Characteristics (N=6) (Mean ± SD)
A ge(yr) 22.8±3.1
Height (cm) 171.5±9.1
Body Weight (kg) 62.4±4.7
Percent Body Fat (%) 12.5±5.5
Fat Free Mass (FFM) (kg) 54.9±6.9
Fat Mass (kg) 7.7±3.3
Table 2. Exercise Descriptive Characteristics (N=6) (Mean±SD)
VOapeak treadmill (1 min ') 3.1±0.3
V O zpak treadmill (ml kg' min^) 49.7±3.9
V O înux cycle (1 min ') 2.8±0.5
V 02m ix cycle (ml kg ' min ') 46.7±5.2
V O 2 at V T  treadmill (1 min ') 2.1±0.4
V O 2 at V T  treadmill (ml kg ' min"') 32.6±5.2
V O 2 at V T  cycle (1 min ') 1.8±0.3
VO 2 at VT cycle (ml kg"' min"') 28.5±4.2
VO2  at 70% VT treadmill (1 min"') 1.4±0.3
VO2  at 70% VT treadmill (ml kg ' min ') 22.8±3.6
VO2  at 70% VT cycle (1 min ') 1.2±0.2
VO2  at 70% VT cycle (ml kg ' min"') 20.1±2.8
Percent V02peak at 70%VT treadmill (%) 45.7±5.6
Percent V02peak at 70%VT cycle (%) 43.2±6.3
Average Percent Grade on the Treadmill at 70%VT walking at 4 mph 4.7±1.9
Average watts on the cycle at 70%VT (W) 70.5±19.0
Average self selected watts on the arm ergometer (CHO trial) 22.2Ü0.9
Average self selected watts on the arm ergometer (PLA trial) 22.8±12.2
Table 3. Blood Data (N=6) (Mean±SD)
Pre Exercise Mid Exercise Post Exercise
PLA CHO PLA CHO PLA CHO
Blood G lucose(m M ) 4.4±0.3 4.44:0.2 4.04:0.1* 4.1=t0.2* 3.94=0.2* 4.05±0.2*
Whole blood
B lood G lucose (mM ) 7.2±1.7 7.04:0.6 5.9=t0.9* 6.24:1.2* 5.5±1.7* 5.84:0.9*
Finger stick
Insulin(pIU/m l) 35.34=33.7 34.64=34.0 14.84:25.9* 14.24:20.3* 12.74:21.9* 13.74=23.0*
Lactate(mM ) 1.34=0.4 1.5±0.6 1.14:0.5 0.9±0.3* l.l=fc0.4 0.8=t0.2*
*p<0.05 main effect for time
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Figure 4. Average Respiratory Exchange Ratio (RER) on the TM during 10 hours of 
exercise. *p<0.05 main effect-time, f  p<0.05 trial by time interaction.
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Figure 5. Average carbohydrate oxidation on the TM across 10-hours of exercise. 
*p<0.05 main effect-time, t  P<0.05 trial by time interaction.
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Figure 6. Average fat oxidation on the TM throughout 10 hours o f exercise. * p<0.05 
main effect for time, f  p<0.05 trial x time interaction.
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Figure 7. Heart Rate values for the cycle during the CHO and PLA trials. * p<0.05, main 
effect for time.
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Figure 8. Heart rate values on the TM during the CHO and placebo trials. 
*p<0.05, main effects for time.
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Figure 9. Rating of Perceived Exertion (RPE) data on the TM for the CHO and PLA 
trials. No difference between trials, but significant main effects- time, * p<0.05.
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Figure 10. Average Blood Glucose (mM) across 10 hours of exercise using the 
indwelling sensor. No interaction or main effect.
58
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9
7
I dft
O) tn1
CO
5
3
0 100 200 300 400 500 600 700
Tim* (min)
I  □  placebo — CHO |
Figure 11. Average blood glucose across 10-hours of exercise (every 5 minutes) with the 
indwelling sensor (mean±sd). There was no interaction or main effect.
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Figure 12. Muscle glycogen pre and post exercise in each trial. * p<0.05 from pre values, 
t  p<0.05 from PLA trial. 44% and 13% change in muscle glycogen pre to post exercise 
for the PLA and CHO trial respectively.
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Figure 13. Average change in muscle glycogen pre-to post-exercise using an ANCOVA. 
* p<0.05 vs. PLA trial.
61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5  -
h
L
5.4  ± 2.2
2,2 ± 1.8
Trial
□  Placebo ■  Carbohydrate
Figure 14. Rates of muscle glycogenolysis for the CHO and PLA trials by ANCOVA. 
Values expressed as mean±sd. *p<0.05 vs. placebo.
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Informed Consent Form
Effects o f carbohydrate feedings on blood glucose and muscle glycogen during extended exercise
Principal Investigator: Brent C. Ruby, Ph D.
Location: Human Performance Laboratory
McGill Hall #121 
The University o f  Montana 
Missoula, MX 59812 
(406) 243-2117/(406) 243-4780
Purpose
The purpose o f  this project is to determine the effects o f  high carbohydrate food/drink sources on blood 
glucose, and changes in muscle glycogen extended exercise. The information collected in this study will 
help determine if  the effects o f supplemental carbohydrate consumption will alter work performance and 
minimize fatigue during extended exercise/work bouts.
As a participant in this study you will complete the following assessments. 1) a pre-screening assessment 
which involves a health/exercise history questiormaire (Par-Q), 2) a measure o f  percent body fat obtained 
using a underwater weighing, 3) a maximal treadmill test and maximal cycle ergometer test to measure 
aerobic fitness levels, 4) two ten-hour worik/rest sessions involving cycling, treadmill walking and arm 
exercise, 5) the completion o f a mood state survey (the Profile o f Mood States) at six times during the 
study, 5) collection o f  expired gases to determine fuel use during the 10-hour work/rest session, 6) 
consumption o f  one o f two different types o f  liquid carbohydrate every hour o f  exercise, 7) finger-stick 
blood samples every two hours and venous blood samples (obtained from an arm vein) to determine blood 
glucose, lactate, and epinephrine before, during, and after activity, 8) measures o f cognitive performance 
using a computer reaction time test, 9) saliva samples collected at various times before, during and after 
each exercise session, 10) a total o f four muscle biopsies (two muscle biopsies per 10-hr trial: a) ezirly in 
the morning before the exercise session begins, and b) late in the afternoon after the exercise session is 
completed).
Body Fat Measurement -  Underwater Weighing:
This test session will require that you do not eat for a minimal o f  3 hours prior to the testing. 
Prior to the test, body weight will be recorded in your bathing suit. You will then be asked to 
complete between 3 - 6  underwater weighing procedures. The underwater weight requires 
that you are submersed in our weighting tank (similar to a hot tub) and that you maximally 
exhale as much air as possible while underwater. The underwater weight will be recorded 
within 2-4 seconds and then you will be signaled to surface. This procedure will be repeated 
until three measurements have been obtained that are within 100 grams o f each other. A nose 
clip will be provided upon request. This test will take approximately 30 minutes.
Maximal Exercise Test -  Treadmill:
This test will consist o f walking and running on a motorized treadmill to a maximal effort. 
The speed and grade o f the treadmill will progress to fatigue. You will be encouraged to 
continue to walk/run until exhaustion. During the entire testing session on the treadmill, you 
will wear a nose clip and headgear that will support a mouthpiece. This will allow us to 
measure the amount o f  oxygen the body uses during the exercise. Heart rate will be measured 
using an elastic chest strap that is worn on the skin under your shirt around your chest. This 
test will take approximately 45 minutes to 1-hour. You will be asked to fast for 
approximately 3 hours prior to this test.
Maximal Exercise Test -  Cycle:
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This test will consist o f  riding on a laboratory exercise cycle to maximal effort. The 
resistance o f  the cycle will increase each minute and will progress to fatigue. You will be 
encouraged to continue to ride until exhaustion. During this test you will wear a nose clip and 
headgear that will support a mouthpiece. This will allow us to measure the amount o f oxygen 
that the body uses during this exercise. Heart rate will be measured using an elastic chest 
strap that is worn on the skin under your shirt around your chest. This test will take 
approximately 45 minutes to 1 hour. You will be asked to fast for approximately three hours 
prior to this test.
lA-bour Exercise/Rest Session:
You will be asked to report to the laboratory after a 12 hour fast, at approximately 6:00 AM. 
Upon arrival, you will be asked to void your bladder and your nude body weight will be 
measured. A cognitive function test using a computer program will evaluate your decision 
making and reaction times. A saliva sample will be collected by having you spit small 
amounts into a plastic tube for approximately 5 minutes. Prior to exercise, a blood sample will 
be obtained from an arm vein. A muscle biopsy will then be obtained from your front thigh 
muscle (this is detailed below). You will then be provided with a small, standardized 
breakfast (apple, granola bar, juice box). Each o f the 10-hr sessions will be completed as 
follows: 9 minutes o f  arm exercise, followed by 1 minute o f rest, followed by 19 minutes o f  
cycling exercise, followed by 1 minute o f rest, followed by 20 minutes o f treadmill walking, 
followed by 10 minutes o f  rest. Each bout o f  arm exercise will be at a self-selected intensity. 
Each exercise bout on the cycle and treadmill will be completed at approximately 40-50% o f  
your maximal capacity. After the completion o f  the fifth 1-hr session, a second blood sample 
will be obtained from an arm vein, which will be followed by the computer cognitive 
performance test and saliva sample. You will then be given a snack lunch and a 40-minute 
rest break. The remaining five 1-hr sessions will be identical to those above (9 minutes o f  
arm exercise, followed by 1 minute o f  rest, followed by 19 minutes o f  cycling exercise, 
followed by 1 minute o f  rest, followed by 20 minutes o f  treadmill walking, followed by 10 
minute o f  rest). After the final 10-minute rest period, a final blood and saliva sample will be 
obtained followed by a post exercise nude body measurement and the post-exercise muscle 
biopsy will be obtained. Following the completion o f  the muscle biopsy, you will be 
provided with a meal in the lab.
Muscle Biopsies:
A total o f  four muscle biopsies will be obtained from your front thigh muscle (vastus lateralis 
-  approximately 6 inches up from the kneecap on the lateral side o f your thigh). The muscle 
biopsy procedure requires Àat the site be sterilized. After the site is cleaned, a small amount 
o f lidocaine will be injected just under the skin surface. Additional small amounts o f  
lidocaine will be injected around a small 1-inch area around the site on the leg. After the area 
is treated with the lidocaine (approximately 5 ml, 1% lidocaine), a small incision 
(approximately 1/4 inch long) will be made through the skin and to a depth o f approximately 
3/4-1.5 inches. The biopsy needle will then be inserted through the incision and the sample 
obtained. After the sample is obtained, the site will be cleaned and closed with steri-strips 
and/or a single stitch and bandaid and wrapped with an ace bandage. A flexible ice pack will 
then be placed on the site for 10 minutes. The biopsy samples will be obtained a) prior to the 
10-hour exercise/rest session, and b) immediately after the 10-hour exercise/rest session (on 
the same leg but approximately 2 inches above the initial sample). This will be repeated for 
the second trial using the opposite leg. The muscle biopsies will be used to evaluate 
alterations in muscle carbohydrate and fat stores in response to physical activity. Latex free 
bandages will be provided if  subjects have a known allergy to latex. All o f  the muscle 
biopsies will be conducted by Dr. Brent Ruby, the study director.
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Body Weight:
Your nude body weight will be measured using a digital scale prior to, after 5-hours, and 
immediately following each 10-hour exercise/rest session. All measures will be done in 
private.
Surveys and Ci^aitive Testing:
You will be asked to complete a 60-question survey that has been developed to assess you 
opinions regarding your current mental state prior to, at the mid point and immediately 
following the each 10-hour exercise/rest session. You are asked to provide an accurate and 
truthful response to each question. You will also complete a computer directed test that will 
measure reaction time and accuracy to a series o f  questions.
Supplemental Carbohydrate Beverage:
During each 10-hour exercise/rest session, you will be given one o f  two different 
carbohydrate-containing beverages. You will be asked to drink a predetermined amount 
(approximately 200 ml, approximately 6.7 oz, just less than 1 cup) o f the solution at the top o f 
each hour and throughout the entire 10-hour session. You will also be provided with a small, 
standardized lunch at the 5-hour midpoint.
Finger stick and arm vein blood samples :
During each 10-hour exercise session, periodic finger stick blood samples will be collected 
prior to and following each hour o f exercise. These samples are being collected to evaluate 
changes in blood sugar throughout each exercise session. Blood samples will also be taken 
prior to the 10-hr exercise session, at the 5-hour midpoint, and immediately after the 10* hour 
o f exercise. These samples will be collected and analyzed for blood sugar, lactate and 
epinephrine.
Risks and Discomfort
1. Mild discomfort may result during and after the exercise. These discomforts include shortness of 
breath, tired or sore legs, nausea and possibility o f  vomiting,
2. Muscle soreness after the tests may occur as a result o f the exercise, but should not persist.
3. Certain changes in body function take place when any person exercises. Some o f these changes are 
normal and others are abnormal. Abnormal changes may occur in blood pressures, heart rate, heart 
rhythm or extreme shortness o f  breath. Very rare instances o f heart attack have occurred, as with other 
moderately strenuous exercise activities. Every effort will be made to minimize possible problems by 
the preliminary evaluation and constant surveillance during testing. A trained CPR technician will be 
on hand at all times and the laboratoiy has standard emergency procedures should any potential 
problems arise.
4. You will be informed o f any new findings that may affect your decision to remain in the study.
5. The muscle biopsy and blood sampling techniques may cause some local and temporary discomfort. It 
is normal to have the sensation o f  a deep tissue bruise around the site o f the muscle biopsy. This pain 
should be manageable and not above the pain associated fi'om a “charlie horse” type bruise.
6. There is a minor risk o f  infection associated with blood sampling and the muscle biopsy. Should you 
notice unusual redness, swelling or drainage at the biopsy incision site, you should seek medical 
attention and then notify Brent Ruby, study director.
7. There are minimal risks associated with the use o f  lidocaine (the local anesthetic). The risk o f a 
reaction to the lidocaine is extremely low (approximately 1/1,000,000). However to minimize this 
risk, no more than 5-9 ml o f  a 1% lidocaine solution will be used per biopsy.
8. During any o f  the exercise tests should symptoms, such as chest discomfort, unusual shortness of 
breath or other abnormal findings develop, the exercise physiologist conducting the research will 
terminate the test. Guidelines by the American College o f Sports Medicine will be followed to 
determine when a test should be stopped. These symptoms include moderate to severe angina (chest 
pain), increased dizziness, shortness o f  breath, fatigue and your desire to stop.
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9. You will be excluded from participation if  you have a known history o f allergic reactions to local 
anesthetics.
Benefits of Participating in This Study
1. Upon completion o f the preliminary tests (body fat, treadmill, cycle and arm ergometer max tests), you 
will be paid $25. Upon completion of the first 10-hour exercise/rest session, you will be paid another 
$75. Upon completion o f the second 10-hour session, you will be paid another $100. Therefore, upon 
completion o f the entire study, you will be paid a total of $200. If you decide to withdraw at any time, 
you will be compensated for the test sessions you have completed or initiated.
2. The information from these tests will provide you with an accurate assessment o f you aerobic fitness 
and body composition that can be compared with norms for your age and sport but may be of little 
benefit to your understanding of your personal fitness. There are no other direct benefits to the 
participants in the study.
3. There is no promise that you will receive any benefit outside o f the financial payment as a result o f 
taking part in this study.
Confidentiality
All results will be kept in strict confidence among the subject involved and the Principal Investigators and 
other Co-Investigators. During the entire period of data collection, subject records will be kept within the 
Human Performance Laboratory and will be locked under the direction of the Principal Investigator.
Compensation for Injury
Although we believe that the risk o f taking part in this study is minimal, the following liability statement is 
required in all University o f Montana consent forms. In the event that you are injured as a result o f this 
research you should individually seek appropriate medical treatment. I f the injury is caused by negligence 
o f the University or any o f its employees, you may be entitled to reimbursement pursuant to the 
Comprehensive State Insurance Plan established by the Department o f Administration under the authority 
o f M.C.A., Title2, Chapter 9. In the event o f  a claim fo r  such injury, further information may be obtained 
from the University’s Claim representative or University Legal Counsel.
Voluntary Participation and Withdraw!
It is important that you realize that you are free to withdraw from the study at any time. As mentioned 
above, even if  you decide to drop out o f the study, you will receive full compensation for all the test 
sessions you complete or initiate.
A copy o f this consent form will be provided for you at your request. In addition, the data collected during 
this study will be done at no cost to you.
Statement of Consent
I have read the above statements and understand the risks involved with this study. I authorize Brent C. 
Ruby and such assistants that he may designate, to administer and conduct the testing as safely as possible 
with a minimal amount of discomfort. If I have additional questions, I may contact Brent C. Ruby at home 
(406) 542-2513 or at the Human Performance Laboratory (406) 243-2117.
Participant (print)
Signature   Date
Permanent Mailing Address ____________________________________________
(for payment purposes) ____________________________________________
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InvestigatorAVitness Signature ____________________________________________
(print)
Investigator/Witness Signature ____________________________________________  Date
Subject statement of consent to be photographed during data collection
During the study, I understand that pictures may be taken. I provide my consent to having my picture taken 
during the course o f the research study. I provide my consent that my picture may be used in some 
presentations related to this study. If pictures are used at any time for presentation, names will not be 
associated with them.
Signature    Date _______
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APPENDICES B
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10 Hour Female Study- Anne McCiaughry
Subject # Age Height (cm) Weight (kg) % Body Fat
TM
V02max TM V02vt
TM 70% 
V02vt
1 21 157 56.2 16.8 3.13 1.93 1.35
2 23 171.2 62.1 12.9 3.03 2.19 1.53
3 25 167.6 60.2 11.5 2.95 1.71 1.2
4 27 171.5 60.8 17.8 2.64 1.48 1.03
5 23 179.1 68.3 13.8 3.48 2.6 1.82
6 18 182.9 67.8 2.3 3.43 2.4 1.68
Avg. 22.83333 171.55 62.56667 12.51667 3.11 2.051667 1.435
St dev 3.125167 9.09126 4.684727 5.540187 0.313879 0.424142 0.297909
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Subject # Trial
Pre Weight 
(kg)
Post 
Weight (kg) ml drink
UBE Watts 
1
UBE Watts 
2
UBE Watts 
3
1 A 56.3 55.2 140 15.1 12 12
2 A 63.2 63 162 39.11 40 40
3 A 59.4 59.5 160 19.11 29 29
4 A 60.8 60.6 150 5.78 9 9
5 A 68.8 67.5 177 18.2 18 18
6 A 69.5 67.9 199 35 30 30
Avg. 63 62.28333 164.6667 22.05 23 23
St dev 5.265358 4.899558 20.89657 12.61133 11.96662 11.96662
difference 0.716667
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Subject # Trial
Pre Weight 
(kg)
Post 
Weight (kg) ml drink
UBE Watts 
1
UBE Watts 
2
UBE Watts 
3
1 B 56.7 55.6 140 13.11 14 14
2 B 62.3 62.4 162 37 35 35
3 B 60 59.6 160 19.2 29 29
4 B 59.5 59.8 150 5.33 8 8
5 B 69.6 68.4 177 16.78 18 18
6 B 69.8 67.8 199 35 30 30
Avg. 62.98333 62.26667 164.6667 21.07 22.33333 22.33333
St dev 5.499606 5.017835 20.89657 12.49656 10.55778 10.55778
difference 0.716667
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iseline Testing Baseline Testing Baseline Testing
TM VT%  
grade
TM 70% 
grade
CYCLE
V02max
CYCLE
V02vt
CYCLE 
70% V02vt
CYCLE 
V r Watts
CYCLE 
70% Watts
V02 peak 
TM 
ml/kg/mi n
11 4 2.94 1.81 1.27 160 70 55.6
12 5.5 2.19 1.66 1.16 130 48 48.8
11 3.5 2.79 1.42 0.99 140 60 49.1
7 2 2.45 1.56 1.09 160 60 43.5
14 7.5 2.98 2.31 1.62 200 85 50.9
14 5.5 3.59 2.04 1.43 180 100 50.6
11.5 4.666667 2.823333 1.8 1.26 161.6667 70.5 49.75
2.588436 1.914854 0.483225 0.328451 0.232551 25.62551 19.01315 3.915482
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts SS HR Cyc
4 5 6 7 8 9 10 1
12 12 12 12 12 12 11.33 126
40 40 40 40 40 40 45 114
29 29 29 29 29 29 18 109
9 9 9 9 9 9 6.67 123
18 18 18 18 18 18 15.78 126
30 30 30 30 30 30 36.67 118
23 23 23 23 23 23 22.24167 119.3333
11.96662 11.96662 11.96662 11.96662 11.96662 11.96662 15.14863 6.918574
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts UBE Watts SS HR Cyc
4 5 6 7 8 9 10 1
14 14 14 14 14 14 12.6 127
35 35 35 35 35 35 39.5 110
29 29 29 29 29 29 19.7 114
8 8 8 8 8 8 5.22 114
18 18 18 18 18 18 20.2 132
30 30 30 30 30 30 37.5 114
22.33333 22.33333 22.33333 22.33333 22.33333 22.33333 22.45333 118.5
10.55778 10.55778 10.55778 10.55778 10.55778 10.55778 13.5921 8.803408
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Baseline testing
V02 peak 
cycle 
ml/kg/min
V02 at VT 
TM ml/kg/ 
min
V02 at VT 
cycle 
ml/kg/min
V02at 
70% VT TM
V02 at 
70% VT 
cycle
%V02peak 
at 70% VT 
TM 
ml/kg/min
%V02peak 
at 70% VT 
cyle
Avg. % 
V02 cycle 
&TM
52.6 34.4 32.3 24.02135 22.59786 43.20387 42.96172 44.4618
45.9 35.3 26.1 24.63768 18.67955 50.48705 40.69619
45.7 28.5 23.3 19.93355 16.44518 40.59787 35.98508
39.6 24.2 25.27 16.94079 17.92763 38.94434 45.2718
43.7 38.06 33.9 26.64714 23.71889 52.35195 54.27663
53 35.39 30.1 24.77876 21.09145 48.96988 39.79518
46.75 32.64167 28.495 22.82655 20.07676 45.75916 43.16443
5.206438 5.205483 4.228303 3.636686 2.842884 5.580981 6.276148
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc
2 3 4 5 6 7 8 9
116 110 116 115 105 120 106 117
113 113 114 116 118 112 110 109
102 98 99 101 116 106 106 103
117 105 101 102 124 113 92 110
128 120 131 124 140 138 127 135
116 112 110 113 125 119 113 116
115.3333 109.6667 111.8333 111.8333 121.3333 118 109 115
8.334667 7.501111 11.61752 8.841191 11.62182 11.04536 11.3842 11.04536
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc SS HR Cyc
2 3 4 5 6 7 8 9
127 126 122 121 121 127 119 128
107 103 101 103 100 107 102 100
107 107 106 106 112 114 105 111
111 110 111 108 109 109 108 108
129 120 126 125 132 126 124 127
114 111 114 116 117 116 113 114
115.8333 112.8333 113.3333 113.1667 115.1667 116.5 111.8333 114.6667
9.80646 8.565434 9.458682 8 841191 10.9438 8.408329 8.471521 10.98484
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Stdev
Fat Free 
Mass
5.822252 46.77
54.09
53.318
49.95
58.86
66.27
54.87633
6.909607
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
SS HR Cyc SS HR TM SS HR TM SS HR TM SS HR TM SS HRTM SS HR TM SS HR TM
10 1 2 3 4 5 6 7
117 130 123 122 124 126 137 131
118 145 139 135 137 142 146 142
107 122 115 114 116 120 128 119
119 133 124 121 117 121 130 124
142 150 143 150 153 154 159 151
121 141 122 120 122 141 139 135
120.6667 136.8333 127.6667 127 128.1667 134 139.8333 133.6667
11.53545 10.38107 10.87505 13.20606 14.30268 13.72589 11.40906 11.72462
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
SS HR Cyc SS HR TM SS HR TM SS HR TM SS HR TM SS HR TM SS HR TM SS HR TM
10 1 2 3 4 5 6 7
121 137 126 124 126 124 133 130
116 146 136 132 133 132 104 136
113 121 113 115 112 121 126 124
113 129 128 129 129 125 128 124
135 151 142 141 142 143 146 140
115 124 123 121 122 122 127 127
118.8333 134.6667 128 127 127.3333 127.8333 127.3333 130.1667
8.447879 12.1106 10.13903 9.099451 10.15218 8.376555 13.61861 6.585337
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
SS HR TM 
8
SS HR TM 
9
SS HRTM 
10
Blood
Glucose
Pre
Blood
Glucose
1
Blood
Glucose
2
Blood
Glucose
3
Blood
Glucose
4
125 126 130 181.67 165.00 132.50 124.50 116.58
139 136 138 110.33 104.08 100.38 79.33 75.5
121 118 127 92 97.66 93.91 99.83 94.83
124 129 135 120 92.08 87.41 107.08 120.33
154 156 146 148 122.33 119.16 127.08 130
131 133 138 121 117.66 92.66 115 108.66
132.3333 133 135.6667 128.8333 116.4683 104.3367 108.8033 107.6506
12.38817 12.86857 6.713171 31.61497 26.43148 17.66427 17.72562 19.69317
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
SS HR TM 
8
SS HR TM 
9
SS HR TM 
10
Blood
Glucose
Pre
Blood
Glucose
1
Blood
Glucose
2
Blood
Glucose
3
Blood
Glucose
4
129 128 136 114.66 115 118 122.5 116.5
132 133 141 87.66 65 105 138.66 130.91
120 119 124 126 116.08 109.83 109.66 113.08
123 122 135 174.66 142.66 132.16 128.33 119.33
137 142 147 97 106.33 129.58 128.33 127.41
130 122 127 114.66 110.33 100 105.83 102.66
128.5 127.6667 135 119.1067 109.2333 115.7617 122.2183 118.315
6.156298 8.640988 8.5557 30.49864 25.1543 13.14755 12.42097 10.18
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Blood
Glucose
5
Blood
Glucose
Lunch
Blood
Glucose
6
Blood
Glucose
7
Blood
Glucose
8
Blood
Glucose
9
Blood
Glucose
10
Glucometer
Reading
Pre
91.25 92.50 105.42 110.17 103.25 80.92 77.50 180
68.83 73.33 68.58 83 66.41 86.25 70.5 104
89.58 93.66 104.16 73.33 61.75 65.83 77.41 96
115.08 99.87 110.08 110.33 110.33 107.33 114 127
136.16 137.83 142.66 125.08 145.16 147.25 160.91 148
107.41 114.33 126.25 131.66 125.08 118.33 123.83 124
101.385 101.92 109.5244 105.5944 101.9967 100.9844 104.025 129.8333
23.38828 22.0095 24.90027 23.03881 32.72043 29.45264 35.39351 30.66214
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Blood
Glucose
5
Blood
Glucose
Lunch
Blood
Glucose
6
Blood
Glucose
7
Blood
Glucose
8
Blood
Glucose
9
Blood
Glucose
10
Glucometer
Reading
Pre
111.16 98.5 108.33 129.66 123.41 116.83 120.91 124
126 121.83 116.08 120.16 122 116.16 110.58 149
111 115.16 106.66 107.75 112.75 106.41 107.08 120
115.08 139.6 107.66 112.41 114.66 116.66 75.58 127
119.16 114.5 112.91 104.25 108.75 110 124.75 119
89.16 99.83 93.75 102.66 97 94.91 95 122
111.9267 114.9033 107.565 112.815 113.095 110.1617 105.65 126.8333
12.49072 15.19478 7.659527 10.39235 9.65603 8.595225 18.11991 11.23239
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Blood Blood Blood
Glucometer Glucometer Glucometer Glucometer Glucometer Glucose Glucose Glucose
Reading Reading Reading Reading Reading Assay mM Assay mM Assay mM
Lunch Post Pre(mmol) Lunch Post (pre) (lunch) (post)
90 72 9.944751 4.972376 3.977901 4.376 3.975 3.816
97 76 5.745856 5.359116 4.198895 4.345 4.197 3.985
96 86 5.303867 5.303867 4 751381 4.915 4.144 4.133
101 105 7.016575 5.58011 5.801105 4.242 3.787 3.737
133 155 8.176796 7.348066 8.563536 4.101 3.959 4.01
121 108 6.850829 6.685083 5.966851 4.222 3.909 3.697
106.3333 100.3333 7.173112 5.87477 5.543278 4.366833 3.995167 3.896333
16.82459 30.55923 1.694041 0.929535 1.688355 0.285753 0.151895 0.17226
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Blood Blood Blood
Glucometer Glucometer Glucometer Glucometer Glucometer Glucose Glucose Glucose
Reading Reading Reading Reading Reading Assay mM Assay mM Assay mM
Lunch Post Pre (mmol) Lunch Post (pre) (lunch) (post)
115 97 6.850829 6.353591 5.359116 4.376 4.186 4.123
96 101 8.232044 5.303867 5.58011 4.26 4.334 4.207
112 111 6.629834 6.187845 6.132597 4.493 4.345 4.197
152 126 7.016575 8.39779 6.961326 4.484 4.131 4.03
97 114 6.574586 5.359116 6.298343 3.989 3.878 4.01
96 79 6.740331 5.303867 4.364641 4.606 3.878 3.737
111.3333 104.6667 7.007366 6.151013 5.782689 4.368 4.125333 4.050667
21.64871 16.20699 0.620574 1.196061 0 895414 0.219588 0.208737 0.1741
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE 1 RPE 3 RPE 5 RPE 6 RPE 8 RPE 10
V02
(L/min)
TM1
V02 
(L/min) 
TM 3
12 10 11 10 12 12 1.4 1,35
11 11 11 12 12 12 1.57 1.51
11 12 12 13 13 15 1.15 1.14
10 11 10 10 11 12 1.32 1.16
11 13 13 14 15 15 1.77 1.78
12 12 13 12 13 12 1.83 1.55
11.16667 11.5 11.66667 11.83333 12.66667 13 1.506667 1.415
0.752773 1.048809 1.21106 1.602082 1.36626 1.549193 0.265079 0.247123
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
RPE 1 RPE 3 RPE 5 RPE 6 RPE 8 RPE 10
V02
(L/min)
TM1
V02 
(L/min) 
TM 3
11 10 10 10 10 10 1.56 1.47
11 11 11 11 11 11 1.53 1.44
11 11 12 13 14 15 1.26 1.19
11 11 11 11 12 12 1.23 1.08
14 14 13 15 14 13 1.78 1.72
11 11 12 12 13 12 1.62 1.49
11.5 11.33333 11.5 12 12.33333 12.16667 1.496667 1.398333
1.224745 1.36626 1.048809 1.788854 1.632993 1.722401 0.213417 0.229558
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
V02 
(L/min) 
TM 5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
VC02 
(L/min) TM 
1
VC02 
(L/min) TM 
3
VC02 
(L/min) TM 
5
VC02 
(L/min) TM 
6
1.4 1.43 1.39 1.41 1.17 1.14 1.14 1.18
1.57 1.59 1.51 1.58 1.44 1.39 1.33 1.36
1.22 1.25 1.25 1.27 1.07 1.02 0.99 1.11
1.12 1.17 1.19 1.22 122 1.03 0.96 1.1
1.81 1.8 1.84 1.86 162 1.56 1.52 1.55
1.64 1.66 1.67 1.66 1.69 1.39 1.36 1.53
1.46 1.483333 1.475 1.5 1.368333 1.255 1.216667 1.305
0.262221 0.244268 0.24962 0.245357 0.253883 0.222957 0.22295 0.204622
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
V02
(L/min)
TM5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
VC02 
(L/min) TM 
1
VC02 
(L/min) TM 
3
VC02 
(L/min) TM 
5
VC02 
(L/min) TM 
6
1.34 1.39 1.45 1.38 1.28 1.36 1.19 1.15
1.47 1.62 1.5 1.57 1.4 1.35 1.35 1.56
1.19 1.3 1.3 1.31 1.15 1.1 1.08 1.12
1.12 1.15 1.07 1.18 1.14 1 1.03 1.07
1.81 1.89 1.75 1.83 1.63 1.6 1.64 1.68
1.54 1.55 1.58 1.55 1.52 1.44 1.48 1.44
1.411667 1.483333 1.441667 1.47 1,353333 1.308333 1.295 1.336667
0.252144 0.261508 0.234897 0.229695 0.199366 0.221487 0.238223 0.257423
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
VC02 
(L/min) TM 
8
VC02 
(L/min) TM 
10 RERTM 1 RERTM 3 RERTM 5 RERTM 6 RERTM 8 RER TM 10
1.14 1.12 0.835714 0.844444 0.814286 0.825175 0.820144 0.794326
1.32 1.27 0.917197 0.92053 0.847134 0.855346 0.874172 0.803797
1.06 1.01 0.930435 0.894737 0.811475 0.888 0.848 0.795276
1.03 1 0.924242 0.887931 0.857143 0.940171 0.865546 0.819672
1.6 1.51 0.915254 0.876404 0.839779 0.861111 0.869565 0.811828
1.43 1.35 0.923497 0.896774 0.829268 0.921687 0.856287 0.813253
1.263333 1.21 0.907723 0.886803 0.833181 0.881915 0.855619 0.806359
0.225979 0.202682 0.035691 0.025312 0.018198 0.043291 0.01977 0.010285
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
VC02 
(L/min) TM 
8
VC02 
(L/min) TM 
10
RERTM
1
RERTM
3
RERTM
5
RER TM 
6
RERTM
8
RER TM 
10
1.23 1.13 0.820513 0.92517 0.88806 0.827338 0.848276 0.818841
1.38 1.42 0.915033 0.9375 0.918367 0.962963 0.92 0.904459
1.18 1.16 0.912698 0.92437 0.907563 0.861538 0.907692 0.885496
0.98 1.06 0.926829 0.925926 0.919643 0.930435 0.915888 0.898305
1.58 1.61 0.91573 0.930233 0.906077 0.888889 0.902857 0.879781
1.53 1.46 0.938272 0.966443 0.961039 0.929032 0.968354 0.941935
1.313333 1.306667 0.904846 0.93494 0.916792 0.900033 0.910511 0.888136
0.227303 0.21997 0.042418 0.016184 0.02447 0.050231 0.038483 0.040356
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Trial A Trial A Trial A
g/min CHO 
1
g/min CHO 
3
g/min CHO 
5
g/min CHO 
6
g/min CHO 
8
g/min CHO 
10
Total g/min 
CHO on TM
g/min FAT 
1
0.8295 0.8535 0.693 0.7787 0.7251 0.5699 148.3233 0.3841
1.5123 1.4774 1.0118 1.0841 1.1589 0.7067 231.7067 0.2171
1.177 0.9816 0.5883 1.038 0.8105 0.5188 170.4733 0.1336
1.3138 0.9629 0.7728 1.2493 0.8666 0.6338 193.3067 0.167
1.6893 1.3842 1.1059 1.2745 1.3736 0.8999 257.58 0.2505
1.8152 1.349 0.9236 1.6329 1.1458 0.8139 256.0133 0.2338
1.389517 1.1681 0.849233 1.17625 1.013417 0.6905 209.5672 0.231017
0.36074 0.264935 0.198077 0.286066 0.250711 0.145999 45.81741 0.086722
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
g/min CHO 
1
g/min CHO 
3
g/min CHO 
5
g/min CHO 
6
g/min CHO 
8
g/min CHO 
10
Total g/min 
CHO on TM
g/min FAT 
1
0.8164 1.4693 1.1131 0.7706 0.942 0.7117 194.1033 0.4676
1.4587 1.5201 1.4238 1.8978 1.464 1.4213 306.19 0.2171
1.1879 1.1851 1.0941 0.923 1.196 1.0729 221.9667 0.1837
1.2387 1.0832 1.0913 1.177 1.0243 1.0352 221.6567 0.1503
1.7027 1.7588 1.6519 1.5771 1.5715 1.4512 323.7733 0.2505
1.7158 1.7691 1.7906 1.5765 1.8897 1.6675 346.9733 0.167
1.353367 1.464267 1.3608 1.320333 1.347917 1.226633 269.1106 0.239367
0.344484 0.284943 0.309371 0.434889 0.360436 0.348748 64.07186 0.117455
59.54333
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
g/min FAT 
3
g/min FAT 
5
g/min FAT 
6
g/min FAT 
8
g/min FAT 
10
Total g/min 
FAT on TM
Total Water 
consumed 
(L)
Total Void 
(L)
0.3507 0.4342 0.4175 0.4175 0.4843 82.94333 1.1 0.5
0.2004 0.4008 0-3841 0.3173 0.5177 67.91333 2.3 1.5
0.2004 0.3841 0.2338 0.3173 0.4342 56.78 3 2.6
0.2171 0.2672 0.1169 0.2672 0.3674 46.76 1.75 2.15
0.3674 0.4843 0.4175 0.4008 0.5845 83.5 3.65 1.6
0.2672 0.4676 0.2171 0.4008 0.5177 70.14 3.1 2.6
0.2672 0.406367 0.297817 0.353483 0.4843 68.00611 2.483333 1.825
0.075428 0.078092 0.126045 0.061056 0.075428 14.45798 0.94798 0.80234
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
g/min FAT 
3
g/min FAT 
5
g/min FAT 
6
g/min FAT 
8
g/min FAT 
10
Total g/min 
FAT on TM
Total Water 
consumed 
(L)
Total Void
(L)
0.1837 0.2505 0.4008 0.3674 0.4175 69.58333 0.5 0.5
0.1503 0.2004 0.1002 0.2004 0.2505 37.29667 3.15 1.65
0.1503 0.1837 0.3006 0.2004 0.2505 42.30667 3.05 2.3
0.1336 0.1503 0.1336 0.1503 0.2004 30.61667 2 1.2
0.2004 0.2839 0.3507 0.2839 0.3674 57.89333 3.5 2.75
0.0835 0.1002 0.1837 0.0835 0.1503 25.60667 3.825 4.525
0.1503 0.194833 0.244933 0.214317 0.272767 43.88389 2.670833 2.154167
0.040906 0.066521 0.123022 0.099875 0.101124 16.80881 1.22927 1.406984
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First Assay Run
Trial A Trial A Trial A Trial A Trial A Trial A DIFA
Urine
Nitrogen
Protein
Metabolism
Time Bkfet 
to Exerc 
(min)
Time Exerc 
to post 
biopsy 
(min)
Muscle
glycogen
pre
Muscle
Glucogen
Post Mus Gly delta
1628 16:18 19:32 149.8409 104.5413 -45.2996
625 18:05 18:42 182.1823 110.0082 -72.1741
286 20:30 26:00:00 136.5164 101.838 -34.6784
365 40:10:00 22:59 192.202 125.6912 -66.5108
439 16:43 20:32 208.5 128.08 -80.42
363 21:36 21:00 212.33 185.32 -27.01
617.6667 #DIV/0! 0.972083 0.894097 180.2619 125.9131 -54.34881667
508.2219 #DIV/0! 0.401507 0.110761 31.01971 31.05883 21.73285842
Trial B Trial B Trial B Trial B Trial B Trial B DIFB
Urine
Nitrogen
Protein
Metabolism
Time Bkfst 
to Exerc 
(min)
Time Exerc 
to post 
biopsy 
(min)
Muscle
glycogen
pre
Muscle
Glucogen
Post Mus Gly delta Rat
1427 9:08 16:06 149.4063 108.1406 -41.2657
470 20:14 17:38 119.0774 120.2927 1.2153
319 22:36 22:26 131.1275 134.5424 3.4149
474 13:43 21:58 145.4766 119.2637 -26.2129
258 17:09 23:00 149.69 104.2 -45.49
203 25:04:00 17:34 219.14 206.66 -12.48
525.1667 #DIV/0! 0.749306 0.824306 152.3196 132.1832 -20.1364
455.3326 #DIV/0! 0.245636 0.125332 34.87504 38.00464 20.95402343
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Trial A
Rate of 
Glycogenolysis
4.52996
7.21741
3.46784
6.65108
8.042
2.701
5.434881667
2173285842
Trial B
e of Glycogenolysis
4.12657
-0.12153
-0.34149
2.62129
4.549
1.248
2.01364
2.095402343
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APPENDICES C
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Type HI Sums of Squares
Subject 5 13196.514 2639.303
Trial 1 11.169 11.169 .468 .5244 .5244 .5244
Trial * Subject 5 119.386 23.877
Times 9 13.479 1.498 .136 .9984 .7441 .7559
Tim es * Subject 45 497.153 11.048
Trial * Times 9 2.513 .279 .604 .7866 .5543 .6165
Trial * Times * ... 45 20.792 .462
Dependent: UBE (watts)
Means Table 
Effect: Trial * Times 
Dependent: UBE (watts)
Count Mean Std. Dev. Std. Error
A, 1 6 22.050 12.611 5.149
A, 2 6 23.000 11.967 4.885
A, 3 6 23.000 11.967 4.885
A, 4 6 23.000 11.967 4.885
A, 5 6 23.000 11.967 4.885
A, 6 6 23.000 11.967 4.885
A, 7 6 23.000 11.967 4.885
A, 8 6 23.000 11.967 4.885
A, 9 6 23.000 11.967 4.885
A, 10 6 22.242 15.149 6.184
B, 1 6 21.070 12.497 5.102
B,2 6 22.333 10.558 4.310
B,3 6 22.333 10.558 4.310
B ,4 6 22.333 10.558 4.310
B,5 6 22.333 10.558 4.310
B ,6 6 22.333 10.558 4.310
B ,7 6 22.333 10.558 4.310
B, 8 6 22.333 10.558 4.310
B ,9 6 22.333 10.558 4.310
B, 10 6 22.453 13.592 5.549
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 42.267 8.453
Trial 1 3.625 3.625 .424 .5436 .5436 .5436
Trial * Subject 5 42.737 8.547
Time 11 11.188 1.017 1.820 .0726 2005 .1464
Time * Subject 65 30.738. .559
Trial * Time 11 6.513 .592 .619 .8047 .5351 .5855
Trial * Time * ... 55 52.601 .956
Dependent: Blood Glucose
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Means Table 
Effect: Trial * Time 
Dependent: Blood Glucose
A, p re 
A. 1 
A, 2 
A. 3 
A. 4 
A. 5
A, lunch 
A. 6  
A. 7 
A. 8 
A. 9
A. 10
B. pre 
B, 1 
B .2  
B .3  
B .4  
B .5
B. lunch
B .6
B .7
B .8
B .9
B. 10
C ount M ean Std, Dev. Std. Error
6 7.087 1.739 .710
6 6.406 1.454 .594
6 5.739 .972 .397
6 5.985 .975 .398
6 5.921 1.083 .442
6 5.577 1.286 .525
6 5.606 1.211 .494
6 6.024 1.370 .559
6 5.808 1.267 .517
6 5.610 1.800 .735
6 5.555 1.620 .661
6 5.722 1.947 .795
6 6.552 1.678 .685
6 6.008 1.384 .565
6 6.368 .723 .295
6 6.723 .683 .279
6 6.508 .560 .229
6 6.157 .687 .280
6 6.320 .836 .341
6 5.917 .421 .172
6 6.205 .572 .233
6 6.221 .531 .217
6 6.059 473 .193
6 5.811 .997 407
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 210.595 35.099
Trial 1 .105 .105 .044 .8415 .8415 8415
Trial * Subject 6 14.434 2.406
time points 2 11.383 5.692 5.114 .0248 .0477 .0387
time points * Su... 12 13.358 1.113
Trial * time poi... 2 .309 .155 .171 .8445 .7356 .7595
Trial * time poi... 12 10.829 .902
Dependent: finger stick glucose (mM)
86
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Means Table 
Effect: time points
Dependent: finger stick glucose (mM)
C ount M ean Std. Dev. Std. Error
pre 14 6 .077 2.808 .751
lunch 14 5.154 2.381 .636
post 14 4 .854 2.376 .635
Comparison 1 
Effect: time points
Dependent: finger stick glucose (mM)
Cell W eight
Comparison 2 
Effect: time points
Dependent: finger stick glucose (mM)
Cell W eight
pre 1.000 pre 1.000
lunch -1.000 post -1.000
df 1 df 1
Sum of Squares 5.969 Sum of Squares 10.476
Mean Square 5.969 Mean Square 10.476
F-Value 5.363 F-Value 9.412
P-Value .0391 P-Value .0098
G-G .0588 G-G .0220
H-F .0517 H-F .0170
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 .627 .125
Trial 1 .082 .082 2.905 .1490 .1490 .1490
Trial * Subject 5 .140 .028
time points 2 1.028 .514 14.955 .0010 .0068 .0042
time points * Su... 10 .344 .034
Trial 't im e  poi... 2 .041 .020 1.186 .3449 .3295 .3320
Trial 't im e  poi... 10 .172 .017
Dependent: Whole blood glucose (mM)
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Means Table 
Effect: time points
Dependent: Whole blood glucose (mM)
C ount M ean Std. Dev. Std. Error
pre 12 4 .367 .243 .070
lunch 12 4.000 .187 .054
p o st 12 3.974 .184 .053
Comparison 1 
Effect: time points
Dependent: Whole blood glucose (mM)
Comparison 2 
Effect: time points
Dependent: Whole blood glucose (mM)
Cell Weight Cell Weight
pre 1.000 pre 1.000
lunch -1.000 post -1.000
df 1 df 1
Sum of Squares .566 Sum of Squares .931
Mean Square .566 Mean Square .931
F-Value 16.468 F-Value 27.083
P-Value .0023 P-Value .0004
G-G .0098 G-G .0033
H-F .0069 H-F .0020
88
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 4.467 .893
trial 1 1.595 1.595 42.859 .0012 .0012 .0012
trial * Subject 5 .186 .037
time 5 1.354 .271 15.572 .0001 .0018 .0002
time * Subject 25 .435 .017
trial * time 5 .717 .143 5.774 .0011 .0199 .0044
trial * time * S... 25 .621 .025
Dependent: CHO (g/min)
Means Table 
Effect: trial * time 
Dependent: CHO (g/min)
A. 1 
A. 3 
A. 5 
A. 6 
A. 8
A, 10
B. 1 
B .3  
B .5  
B .6  
B .8  
B, 10
C ount M ean Std. Dev. Std. Error
6 1.390 .361 .147
6 1.168 .265 .108
6 .849 .198 .081
6 1.176 .286 .117
6 1.013 .251 102
6 .691 .146 .060
6 1.353 .344 .141
6 1.464 .285 .116
6 1.361 .309 .126
6 1.320 .435 .178
6 1.348 .360 147
6 1.227 .349 .142
Means Table 
Effect: time
Dependent: CHO (g/min)
1
3
5
6 
8 
10
C ount M ean Std. Dev. Std. Error
12 1.371 .337 .097
12 1.316 .305 .088
12 1.105 .364 .105
12 1.248 .359 .104
12 1.181 .344 .099
12 .959 .379 .109
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Comparison 1
Effect: trial * time
Dependent: CHO (g/min)
Cell W eight
A. 1 1.000
A. 3 -1.000
df 1
Sum  of S q u are s .147
M ean S quare 147
F-Value 5.922
P-Value .0224
G-G .0528
H-F .0345
C o m p ariso n  4
Effect: trial * tim e
D ep en d en t: CHO (g/m in)
Cell W eight
A. 1 1.000
A, 8 -1.000
df 1
Sum  of S q u ares .424
M ean S quare .424
F-Value 17.086
P-Value .0004
G-G .0071
H-F .0015
Comparison 2
Effect: trial * time
Dependent: CHO (g/min)
Cell W eight
A, 1 
A. 5
1.000
- 1.000
df 1
Sum  of S q u are s  .876 
M ean S q u are  .876 
F-Value 35.260 
P-Value .0001 
G-G .0009 
H-F .0001
C o m p ariso n  5 
Effect: trial * tim e 
D ep en d en t: CHO (g/m in)
Cell W eight
A. 1 
A. 10
1.000
- 1.000
df 1
Sum  of S q u ares  1.466 
M ean S quare 1.466 
F-Value 59.023 
P-Value .0001 
G-G .0001 
H-F .0001
Comparison 3
Effect: trial * time
Dependent: CHO (g/min)
Cell W eight
A. 1
A. 6
1.000
- 1.000
df 1
Sum of S quares . 136
Mean S quare .136 
F-Value 5.494 
P-Value .0273 
G-G .0586 
H-F .0401
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Comparison 6
Effect: trial * time
Dependent: CHO (g/min)
Cell Weight
df 1
Sum of Squares .037
Mean Square .037
F-Value 1.486
P-Value .2343
G-G .2007
H-F .2249
Comparison 7
Effect: trial * time
Dependent: CHO (g/min)
Cell Weight
B. 1 1.000 B. 1 1.000
B .3 -1.000 B .5 -1.000
df 1
Sum of Squares 1.658E-4
Mean Square 1.658E-4
F-Value .007
P-Value .9355
G-G .7263
H-F .8723
Comparison 8
Effect: trial * time
Dependent: CHO (g/min)
Cell Weight
B, 1
B .6
1,000
- 1.000
df 1
Sum of Squares .003 
Mean Square .003 
F-Value .132 
P-Value .7196 
G-G .4937 
H-F .6330
Comparison 9 
Effect: triai * time 
Dependent: CHO (g/min)
Cell Weight
Comparison 10 
Effect: trial * time 
Dependent: CHO (g/min)
Cell Weight
B. 1 1.000 B, 1 1.000
B .8 -1.000 B, 10 -1.000
df 1 df 1
Sum of Squares 8.91 IE-5 Sum of Squares .048
Mean Square 8.91 IE-5 Mean Square .048
F-Value .004 F-Value 1.940
P-Value .9527 P-Value .1759
G-G .7593 G-G .1671
H-F .8977 H-F .1769
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Comparison 11
Effect: trial * time
Dependent: CHO (g/min)
Cell Weight
Comparison 12
Effect: triai * time
Dependent: CHO (g/min)
Cell Weight
Comparison 13
Effect: trial * time
Dependent: CHO (g/min)
Ceil Weight
A, 1 1.000 A, 3 1.000 A, 5 1.000
B, 1 -1.000 B .3 -1.000 B .5 -1.000
df 1 df 1 df 1
Sum of Squares .004 Sum of Squares .263 Sum of Squares .785
Mean Square .004 Mean Square .263 Mean Square .785
F-Value .158 F-Value 10.595 F-Value 31.612
P-Value .6945 P-Value .0032 P-Value .0001
G-G .4749 G-G .0202 G-G .0013
H-F .6096 H-F .0079 H-F .0001
C o m p a r is o n  14 
E f f e c t  tr ia l  • t im e  
D e p e n d e n t :  C H O  (g /m in )
Cell Weight
C o m p a r is o n  15  
E ffec t: tr ia l  * t im e  
D e p e n d e n t :  C H O  (g /m in )
Cell Weight
C o m p a r is o n  16 
E ffec t: tr ia l  * t im e  
D e p e n d e n t;  CH O  (g /m in )
Cell Weight
A. 6 1.000 A. 8 1.000 A. 10 1.000
B .6 -1.000 B .8 -1.000 B. 10 -1.000
df 1 df 1 df 1
Sum of Squares .062 Sum of Squares .336 Sum of Squares .862
Mean Square .062 Mean Square .336 Mean Square .862
F-Value 2.508 F-Value 13.516 F-Value 34.721
P-Value .1259 P-Value .0011 P-Value .0001
G-G .1363 G-G .0122 G-G -0009
H-F .1344 H-F .0036 H-F 0001
Means Table 
Effect: trial
Dependent: total g CHO (treadmill)
Count M ean Std. Dev. Std. Error
A 6 209 .567 45.817 18.705
B 6 269.111 64.072 26.157
Type III Sums of Squares
Source df Sum of S quares Mean Square F-Value P-Value G-G H-F
Subject 5 29781.348 5956.270
trial 1 10636.226 10636.226 42.859 .0012 .0012 .0012
trial * Subject 5 1240 844 248.169
D ependent: total g CHO (treadmill)
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Type III Sums of Squares
Source df Sum of S quares Mean Square F-Value P-Value G-G H-F
Subject 5 2091.055 418.211
trial 1 1745.645 1745.645 23.796 .0046 .0046 .0046
trial * Subject 5 366.792 73.358
Dependent; total g FAT (treadmill)
Means Table 
Effect: trial
Dependent: total g FAT (treadmill)
C ount M ean Std. Dev. S td. Error
A 6 68 .006 14.458 5.902
B 6 43 .884 16.809 6.862
Means Table 
Effect: Trial
Dependent: urine nitrogen
C ount M ean Std. Dev. Std. Error
p lacebo 6 617.667 508.222 207.481
OHO 6 525.167 455 .333 185.889
Type III Sums of Squares
Source df Sum of S quares Mean Square F-Value P-Value G-G H-F
Subject 5 2285876.417 457175.283
Trial 1 25668.750 25668.750 3.041 .1417 .1417 .1417
Trial * Subject 5 42209.750 8441.950
D ependen t urine nitrogen
Type III S u m s of S q u a re s
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 6827.667 1365.533
Trial 1 .533 .533 .003 .9607 .9607 9607
Trial * Subject 5 996.467 199.293
Times 9 1210.533 134.504 6.314 .0001 .0050 .0001
Tim es * Subject 45 958.667 21.304
Trial * Times 9 199 800 22.200 1.419 .2089 .2760 .2164
Trial * Times * ... 45 704.200 15 649
Dependent: Cycle HR (b/min)
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M eans Tab)*
Effect: Tim es
D ependent: Cycle HR (b/mln)
1
2
3
4
5
6
7
8
9
10
Count M ean Std. Dev. Std. Error
12 118.917 7.561 2 183
12 115.583 8.681 2.506
12 111.250 7.852 2.267
12 112.583 10.131 2 924
12 112.500 8.458 2.442
12 118.250 11.234 3.243
12 117.250 9.392 2.711
12 110.417 9.681 2.795
12 114.833 10.504 3.032
12 119.750 9.687 2.796
C om padson  1 
Effect: Times
D ependent; Cycle HR (bfmin)
Cell Weight
1 1.000
2 -1.000
df 1
Sum of Squares 66.667
Mean Square 66.667
F-Value 3.129
P-Value .0837
G-G .1048
H-F .0850
C om parison 2 
Effect: Times
D ependent; Cycle HR (bfmin)
Cell Weight
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
352.667 
352 667 
16.554 
.0002 
0073 
.0002
C om parison 3 
Effect: Times
Dependent: Cycle HR (b/min) 
Cell Weight
1 1 ooo 1 1.000
3 -1 000 4 -1 000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
240.667
240.667 
11.297 
.0016 
.0174 
.0018
C om parison 4 
Effect: T im es
Dependent: Cycle HR (b/min)
Cell Weight
1 1.000
5 -1.000
df 1
Sum of Squares 247.042
Mean Square 247 042
F-Value 11.596
P-Value .0014
G-G .0165
H-F .0016
C om parison S 
Effect: T im es
D ependent: Cycle HR (tVmln)
Celt Weight
1.000
-1 000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
2.667
2.667 
.125 
,7251 
.4490 
.7168
Com parison 6 
Effect: Times
Dependent: Cycle HR (b/mln)
Cell Weight
1 000
- 1.000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
16.667
16667
.782
,3811
.2571
.3773
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Comparison 7
Effect; Times
Dependent; Cycle HR (b/min)
Comparison 8
Effect: Times
Dependent: Cycle HR (b/min)
Cell Weight
Cell Weight
C om parison  9 
Effect; T im es
D ependent: Cycle HR (b/min) 
Cell Weight
1.000
- 1.000
1.000
- 1.000
df 1
df 1
Sum of Squares 433.500
Mean Square 433.500
F-Value 20.349
P-Value .0001
G-G .0042
H-F .0001
Sum of Squares 100.042
Mean Square 100.042
F-Value 4.696
P-Value .0356
G-G .0665
H-F .0369
1 1.000
10 -1.000
df 1
Sum of Squares 4.167
Mean Square 4.167
F-Value .196
P-Value .6604
G-G .4061
H-F .6524
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 9103.567 1820.713
Trial 1 360.533 360.533 3.004 1436 .1436 1436
Trial * Subject 5 600.067 120.013
Times 9 1034.000 114.889 5.026 .0001 .0242 .0045
Times * Subject 45 1028.600 22.858
Trial * Times 9 406.300 45.144 2.044 .0560 .1593 .0883
Trial ‘ Times * ... 45 994.100 22.091
Dependent: Treadmill HR (b/min)
Means Table 
Effect: Times
Dependent: Treadmill HR (b/min)
1
2
3
4
5
6
7
8
9
10
Count M ean S td . Dev. Std. Error
12 135.750 10.814 3.122
12 127.833 10.026 2.894
12 127.000 10.812 3.121
12 127.750 11.833 3.416
12 130.917 11.309 3.265
12 133.583 13.641 3.938
12 131.917 9.249 2.670
12 130.417 9.539 2.754
12 130.333 10.815 3.122
12 135.333 7.340 2.119
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Comparison 1
Effect: Times
Dependent: Treadmill HR (b/min)
df 1
S um  of S q u a re s 376 .042
M ean  S q u a re 376 .042
F-V alue 16.451
P-V alue .0002
G -G .0121
H-F .0035
Comparison 2
Effect: Times
Dependent: Treadmill HR (t*/min)
Cell W eigfrt
df 1
S um  of S q u a re s  
M ean S q u are  
F-Value 
P-V alue 
G -G  
H-F
4 5 9 3 7 5
459,375
20.097
.0001
.0079
.0017
Comparison 3
Effiect: Times
Dependent: Treadmill HR (b/min)
Cell W eight
1.000 1 1.000
1.000
-1 .000 -1.000
-1 .000
df
Sum  of S q u a res 
M ean S quare  
F-Value 
P-V alue 
G-G 
H-F
384.000
384.000 
16.800 
.0002 
.0116 
.0033
C om p ariso n  4  
E ffec t T im es
D e p e n d e n t T readm ill HR (tt/min)
C om parison  5 
Effect: T im es
D ependent: Treadm ill HR (b/min)
C om parison 6 
Effect: Tim es
D e p en d e n t Treadmill HR (b/min)
CeW W eight
Cell W eight
Ceil W eight
1.000
- 1.000
1.000
- 1.000
1.000
- 1.000
df 1
df 1 Sum  of S q u a res 88.167
df 1 Sum  of S q u a re s 28.167 M ean S quare 88.167
S um  of S q u a re s 140.167 M ean S q u are 28 .167 F-Value 3.857
M ean S q u a re 140.167 F-V alue 1.232 P-Value .0557
F-V alue 6 .132 P-V alue .2729 G-G .0859
P-V alue .0171 G-G .1828 H-F .0806
G-G .0540 H-F .2287
H-F .0402
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Comparison 7
Effect: Times
Dependent: Treadmill HR (b/mln)
Cell Weight
1
8
Comparison 8 
Effect: Times
Dependent: Treadmill HR (b/min) 
Cell Weight
1.000 1 1.000
-1.000 9 -1.000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
170.667
170.667 
7.466 
.0090 
.0426 
.0278
d f
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
176.042
176.042 
7.702 
.0080 
.0410 
.0261
Comparison 9 
Effect: Times
Dependent: Treadmill HR (b/mln)
1
10
Cell Weight
1.000
- 1.000
df 1
Sum of Squares 1.042 
Mean Square 1.042 
F-Value .046 
P-Value .8319 
G-G .4530 
H-F .6305
97
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Type III S u m s o f S q u are s
Source df Sum of Squares Mean Square F-Vatue P-Value G-G H-F
Subject 5 .314 .063
trial 1 .262 .262 23.796 .0046 .0046 .0046
trial * Subject 5 .055 .011
time 5 .208 .042 15.249 .0001 .0005 .0001
time * Subject 25 .068 .003
trial * time 5 .114 .023 9.155 .0001 .0044 .0003
trial * time * S... 25 .062 .002
Dependent; FAT (g/min)
Means Table 
Effect: time
Dependent: FAT (g/min)
Count Mean Std. Dev. Std, Error
12 .235 .099 .028
12 .209 .084 .024
12 .301 .130 .038
12 .271 .122 .035
12 .284 .107 .031
12 .379 .139 .040
1
3
5
6 
8 
10
Means Table 
Effect: trial
Dependent: FAT (g/min)
Count Mean Std. Dev. Std. Error
A 36 .340 118 .020
B 36 .219 .097 .016
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Means Table 
Effect: trial * time 
Dependent: FAT (g/min)
A. 1 
A. 3 
A. 5 
A. 6 
A. 8
A, 10
B. 1 
8 ,3
8 .5
8.6 
8.8 
8. 10
Count Mean Std. Dev. Std. Error
6 .231 .087 .035
6 .267 .075 .031
6 .406 .078 .032
6 .298 .126 .051
6 .353 .061 .025
6 .484 .075 .031
6 239 .117 .048
6 .150 .041 .017
6 195 .067 .027
6 .245 .123 .050
6 .214 .100 .041
6 .273 .101 .041
99
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Comparison 1
Effect: trial * time
Dependent: FAT (g/min)
Cell Weight
Comparison 2
Effect; trial * time
Dependent: FAT (g/min)
Ceii Weight
Comparison 3
Effect: trial * time
Dependent: FAT (g/min)
Ceii Weight
A. 1 1.000 A, 1 1.000 A, 1 1.000
A. 3 -1.000 A, 5 -1.000 A, 6 -1.000
df 1 df 1 df 1
Sum of Squares 004 Sum of Squares .092 Sum of Squares .013
Mean Square .004 Mean Square .092 Mean Square .013
F-Vaiue 1.573 F-Value 36.932 F-Value 5.360
P-Value .2214 P-Value .0001 P-Value .0291
G-G .1949 G-G .0007 G-G .0597
H-F .2160 H-F .0001 H-F .0399
C o m p a r iso n  4  
E ffec t: tr ia l * tim e  
D e p e n d e n t:  FAT (g/m in)
Ceil Weight
A, 1
A, 8
1.000
- 1.000
df 1
Sum of Squares .045 
Mean Square .045 
F-Vaiue 18.015 
P-Value .0003 
G-G 0058 
H-F .0010
C o m p a r iso n  5 
E ffec t: tria l * t im e  
D e p e n d e n t:  FAT (g/m in)
Cell Weight
C o m p a riso n  6 
E ffect: tria l * tim e 
D e p en d e n t: FAT (g/m in)
Cell Weight
A. 1 1.000 B. 1 1.000
A. 10 -1.000 B,3 -1.000
df 1 df 1
Sum of Squares ,192 Sum of Squares .024
Mean Square .192 Mean Square .024
F-Value 77.056 F-Value 9.529
P-Value .0001 P-Value .0049
G-G .0001 G-G .0238
H-F .0001 H-F .0096
C o m p a r iso n  7 
E ffec t: tr ia l * tim e  
D e p e n d e n t:  FAT (g /m in )
Cell Weight
C o m p a r iso n  8 
E ffec t: tria l * tim e  
D e p e n d e n t:  FAT (g /m in)
Cell Weight
C o m p a riso n  9 
E ffect: tria l * tim e  
D e p en d e n t: FAT (g /m in)
Cell Weight
8. 1 1.000 B. 1 1.000 B, 1 1.000
8 ,5 -1.000 B ,6 -1.000 B, 8 -1.000
df 1 df 1 df 1
Sum of Squares .006 Sum of Squares 9 296E-5 Sum of Squares .002
Mean Square .006 Mean Square 9.296E-5 Mean Square 002
F-Value 2.382 F-Value .037 F-Value .754
P-Value .1353 P-Vaiue .8486 P-Value .3936
G-G .1427 G-G .6181 G-G .2922
H-F .1417 H-F 7800 H-F .3603
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Comparison 10
Effect: trial * time
Dependent: FAT (g/min)
Cell W eight
Comparison 11
Effect triai * time
Dependent: FAT (g/min)
Cell W eight
Comparison 12
Effect: trial * time
Dependent: FAT (g/min)
Cell Weight
B. 1 1.000 A. 1 1.000 A. 3 1.000
B, 10 -1.000 B. 1 -1.000 B .3 -1.000
df 1
Sum  of S quares .003 
Mean Square .003 
F-Value 1.340 
P-Value .2580 
G-G .2158 
H-F .2468
df 1
Sum  of S quares 2.092E-4 
Mean S quare 2.092E-4 
F-Value .084 
P-Value .7747 
G-G .5465 
H-F .7022
df 1
Sum of S quares .041 
Mean Square .041 
F-Value 16.414 
P-Value .0004 
G-G .0074 
H-F .0014
C o m p a r i s o n  1 3  
E f fe c t:  t r ia l  * t im e  
D e p e n d e n t :  F A T  (g /m ln )
Cell W eight
C o m p a r i s o n  1 4  
E ffe c t:  t r ia l  * t im e  
D e p e n d e n t :  FA T (g /m in )
Cell W eight
C o m p a r i s o n  15  
E ffd c t: tr ia l  * t im e  
D e p e n d e n t :  FAT (g /m in )
Cell Weight
A. 5 1.000 A, 6 1.000 A. 8 1.000
B ,5 -1,000 B, 6 -1.000 B .8 -1.000
df 1 df 1 df 1
Sum  of S quares .134 Sum  of Squares .008 Sum of Squares .058
Mean Square .134 Mean Square .008 Mean Square .058
F-Value 63.747 F-Value 3.359 F-Value 23.263
P-Value .0001 P-Value .0788 P-Value .0001
G-G .0002 G-G .1036 G-G .0029
H-F .0001 H-F .0901 H-F .0003
C o m p a r i s o n  1 6  
E ffe c t:  t r ia l  * t im e  
D e p e n d e n t :  FA T (g /m in )
Cell W eight
A, 10 1.000
B, 10 -1.000
df 1
Sum  of S quares .134
M ean Square .134
F-Value 53.747
P-Value .0001
G-G .0002
H-F .0001
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Type III Sums of Squares
Source df Sum  of S quares Mean Square F-Value P-Value G-G H-F
Subject 5 31.115 6.223
Trial 1 35.089 35.089 12.143 .0176 .0176 .0176
Trial * Subject 5 14.448 2.890
D ependent; depletion rate (per hour)
Table of Epsilon Factors for df Adjustment 
Dependent: depletion rate (per hour)
G-G Epsilon H-F Epsilon
Trial 1.000 1.000
Type III Sums of Squares
Source df Sum of S quares Mean Square F-Value P-Value G-G H-F
Subject 5 3114.148 622.830
Trial 1 3511.468 3511.468 12.169 .0175 .0175 .0175
Trial * Subject 5 1442.793 288.559
D ependent: glycogen use
Table of Epsilon Factors for df Adjustment 
Dependent: glycogen use
G-G Epsilon H-F Epsilon
Trial 1.000 1.000
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 17616.330 3523.266
Trial 1 .053 .053 .001 .9765 .9765 .9765
Trial * Subject 5 275.021 55.004
time points 2 3569.643 1784.822 11.596 .0025 .0189 .0187
time points * Su... 10 1539.157 153.916
Trial * time poi... 2 5.775 2.887 .095 .9104 .8133 .8422
Trial * time poi... 10 304.646 30.465
Dependent; Insulin plU/ml
102
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Means Table
Effect: Trial * time points
Dependent: Insulin plU/ml
C ount
A, pre 
A, lunch
A, post
B, pre 
B, lunch 
B, post
Comparison 1 
Effect; time points 
Dependent: Insulin plU/ml
Cell W eight
pre
lunch
1.000
- 1.000
df
Sum  of S q u a re s  
M ean S q u are  
F-Value 
P-V alue 
G-G 
H-F
1
2508.951
2508.951 
16.301 
.0024 
.0150 
.0149
M ean Std. Dev. Std. Error
6 35.276 33.684 13.751
6 14.771 25.864 10.559
6 12.660 21.929 8.952
6 34.577 26.836 10.956
6 14.185 20.322 8.297
6 13.715 23.010 9.394
Comparison 2 
Effect: time points 
Dependent: Insulin plU/ml
Cell W eight
pre
post
1.000
- 1.000
df 1
Sum  of S q u are s 2835.526
M ean S quare 2835.526
F-Value 18.423
P-Value .0016
G-G .0121
H-F .0119
Type III S u m s o f S q u are s
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 3.093 .619
Trial 1 .079 .079 .888 .3892 .3892 .3892
Trial * Subject 5 .447 .089
time points 2 1.339 .670 7.004 .0125 .0353 .0285
time points * Su... 10 .956 .096
Trial * time poi... 2 .303 .151 1.338 .3056 .3059 ,3056
Trial * time poi... 10 1.132 .113
Dependent: Lactate (mM)
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Means Table
Effect: Trial * tim e points 
Dependent: Insulin plU/ ml
A, p re  
A, lunch
A, p o s t
B, p re  
B, lunch 
B. p o st
C ount M ean S td . Dev. S td . Error
6 35.276 33.684 13.751
6 14.771 25.864 10,559
6 12.660 21.929 8.952
6 34.577 26.836 10.956
6 14.185 20.322 8.297
6 13.715 23.010 9.394
Comparison 1 
Effect: tim e points 
Dependent: Insulin plU/ ml
Cell W eight
p re
lunch
1.000
- 1.000
df
Sum  o f  S q u a re s  
M ean S q u a re  
F-V alue 
P-V alue 
G-G 
H-F
1
2508.951
2508.951 
16.301 
.0024 
0150 
.0149
Comparison 2 
Effect: time points 
Dependent: Insulin plU/ ml
Cell W eight
p re
p o st
1.000
- 1.000
df 1
Sum  o f  S q u are s 2835.526
M ean S quare 2835.526
F-Value 18.423
P-Va lue .0016
G-G .0121
H-F .0119
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 77.944 15.589
trial 1 .500 .500 .441 .5360 .5360 .5360
trial * Subject 5 5.667 1.133
time 5 17.778 3.556 3.970 .0087 .0476 .0160
time * Subject 25 22.389 .896
trial * time 5 2.500 .500 1.210 .3335 .3363 .3403
trial * time * S. .. 25 10.333 .413
Dependent: RPE
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Effect: time 
Dependent: RPE
Cell Weight
1.000
3 -1.000
df 1
Sum of Squares .042
Mean Square 042
F-Value .047
P-Value .6310
G-G .6064
H-F .7733
Cempamon 2 
Effect: time 
Dependent: RM
Cell Weight
1.000
- 1.000
.375
.375
df
Sum of Squetee 
Mean Square
F-Value .419 
P-Value .5236 
G-G .3722 
H-F .4796
Con^rteen 3 
Effect: time 
Dependent: RPE
Cell Weight
1.000
- 1.000
df 1
Sum of Squares 2.042 
Mean Square 2.042 
F-Value 2280 
P-Value .1436 
6-G 1463
H-F .1484
Comp»nson4 
Effect: time 
Dependent: RPE
Cell Weight
1 1.000
8 -1.000
df 1
Sum of Squares 8.167
Mean Square 8.167
F-Value 9.119
P-Value .0058
G-G .0252
H-F .0099
Comperisen $ 
Effect: time 
Dependent: R M
Cell Weight
1
10
1.000
df 1
Sum of Squwres 9.375 
Mean Square 9.375 
F-Value 10.466 
P-Value .0034 
G-G .0193 
H-f .0064
Means Table 
Effect: time 
Dependent RPE
1
3
5
6 
8 
10
Count Mean Std. Dev. Std. Error
26 10.538 1.630 .320
26 10.462 1.816 .356
26 10.692 1.761 .345
26 10.923 1.998 .392
26 11.538 2.121 .416
26 11.827 1.760 .345
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T y p e  III S u m s  o f S q u a r e s
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 5 .040 .008
trial 1 .040 .040 46 878 .0010 .0010 .0010
trial * Subject 5 .004 .001
time 5 .032 .006 16 314 .0001 .0006 .0001
time * Subject 25 .010 3.951 E-4
trial * time 5 .018 .004 8680 -0001 ,0065 .0008
trial * time * S... 25 .010 4.102E-4
Dependent: rer
Means Table 
Enact: trial * time 
Dependent: rer
Count
1
3
5
6 
8 
10 
1 
3
5
6 
8 
10
Mean Std. Dev. Std. Error
6 .908 .036 .015
6 887 .025 .010
6 833 .018 .007
6 882 .043 .018
6 856 .020 008
6 .806 .010 .004
6 .905 .042 .017
6 935 016 .007
6 .917 .024 .010
6 .900 .050 .021
6 .911 .038 .016
6 .888 .040 .016
M ean s T able  
E ffect: tim e  
D ep en d en t: re r
Count
1
3
5
6 
8 
10
M e a n s  T a b le  
E ffec t: tr ia l 
D e p e n d e n t:  re r
Mean Std. Dev. Std. Error
12 .906 .037 Oil
12 .911 .032 .009
12 .875 .048 .014
12 .891 .046 013
12 .883 .041 .012
12 847 .051 .015
Count Mean Std. Dev. Std. Error
A 36 .862 .043 .007
B 36 .909 .037 ,006
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Comparison 1
EffisGt: trial * tima
Dependent: rer
Comparison 2
Effect: trial
Dependent: rer
C om parison  3 
Effect: trial * time 
D ependen t rer
Comparison 4
Effect: trial * time
Dependent rer
Ce» Weight Ce» Weight Cell Weight Cell Weight
A.1
A, 3
1.000 A.1 
A. 5
1.000 A.1 
A. 6
1.000 A, 1 
A. 8
1.000
-1.000 -1.000 -1.000 -1.000
df 1 df 1 df 1 df 1
Sum of Squares .001 Sum of Squares .017 Sum of Squares .002 Sum of Squares 008
Mean Square .001 Mean Square .017 Mean Square .002 Mean Square .008
F-Vaiue 3.200 F-Value 40.635 --Value 4.871 F-Value 19.854
P-Vaiue .0857 P-Vaiue .0001 P-Value .0367 P-Value .0002
G-G .1093 G-G .0006 6-G .0693 G-G .0053
H-F .1006 H-F .0001 H-F .0532 H-F .0011
C om parison 5 
E ffec t trial * tim e 
D ependent: rer
Ce» Weight
C om parison 6 
Effect: trial * tim e 
D ependent: rer
Ceii Weight
C om parison 7 
E ffec t trial * time 
D ependen t rer
Cell Weight
Com parison S 
Effect; trial* time 
D ependent rer
Ceii Weight
A .1 1.000 B, 1 1.000 B. 1 1.000 B. 1 1.000
A. 10 -1.000 B .3 -1.000 8 ,5 -1.000 B .6 -1.000
df 1
Sum of Squares .031 
Mean Square .031 
F-Value 75.139 
P-Value .0001 
G-G .0001 
H-F .0001
df 1
Sum of Squares .003 
Mean Square .003 
F-Vaiue 6.623 
P-Value .0164 
G-G .0460 
H-F .0294
df 1
Sum of Squares 4.281E-4 
Mean Square 4.281 E-4
F-Vaiue 1.044 
P-Vaiue .3168 
G-G .2433 
H-F .2861
df 1
Sum of Squares 6.950E-5 
Mean Square 6.950E-5 
F-Value .169 
P-Value .6841 
G -6  .4589 
H-F .5828
Comparison 9 
Effect: trial *time 
Dependent: rer
Cell Weight
Comparison 10 
Effect; trial * Oim 
Dependent: rer
Cell Weight
Comparison 11 
Effect: trial * time 
Dependent: rer
CeH Weight
Comparison 12 
Effect: trial " time 
Dependent: rer
Cell Weight
6 .1 1 000 6, 1 1.000 A, 1 1.000 A, 3 1000
6 ,8 -1.000 6, 10 -1.000 6, 1 -1.000 6 ,3 -1.000
df 1 df 1 df 1 df 1
Sum of Squares 9.629E-S Sum of Squares .001 Sum of Squares 2.484E-S Sum of Squares .007
Mean Square 9.629E-5 Mean Square .001 Mean Square 2.484E-S Mean Square .007
F-Value .235 F-Value 2.042 F-Value .061 F-Value 16.945
P-Value .6323 P-Value .1654 P-Value .8076 P-Value .0004
G-G .4237 G-G .1599 G-G .5580 G-G .0078
H-F .5373 H-F .1679 H-F .7014 H-F .0020
Comparison 13 
Effect: trial * time 
Dependent: rer
Cell Weight
Comparison 14 
Effect: trial ’ time 
Dependent: rer
Cell Weight
Comparison IS 
Effect: trial * time 
Dependent: rer
Cell Weight
Comparison 16 
Effect: trial * time 
Dependent; rer
Cell Weight
A, 6 
6 ,5
1 000 A, 6 
6 ,6
1.000 A, 8
6 ,8
1.000 A. 10
B. 10
1 000
-1 000 -1.000 -1.000 -1.000
df 1 df 1 df 1 df 1
Sum of Squares .021 Sum of Squares .001 Sum of Squares .009 Sum of Squares 020
Mean Square .021 Mean Square .001 Mean Square .009 Mean Square 020
--Value 51.123 F-Value 2.400 F-Value 22.035 F-Value 48.906
P-Value .0001 P-Value .1339 P-Vahie .0001 P-Value .0001
G-G .0003 G-G .1410 G-G .0040 G-G .0003
H-F .0001 H-F .1421 H-F .0007 H-F .0001
107
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Type ill Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Vatue G-G H-F
Subject 5 17863.170 3572.634
Trial 1 704.525 704.525 1.260 .3126 .3126 .3126
Trial * Subject 5 2795.834 559.167
Time 1 8322.071 8322.071 26.723 .0036 .0036 .0036
Time * Subject 5 1557.074 311.415
Trial * Time 1 1755.734 1755.734 12.169 .0175 .0175 .0175
T rial‘ Tim e* ... 5 721.396 144.279
Dependent: glycogen
Means Table 
Effect: Trial * Time 
Dependent: glycogen
C ount M ean Std. Dev. Std. Error
p lacebo , P re 6 180.262 31.020 12.664
p lacebo , P o st 6 125.913 31.059 12.680
CHO, P re 6 152.320 34.875 14,238
CHO, P o st 6 132.183 38.005 15.515
Means Table 
Effect: Time 
Dependent: glycogen
C ount M ean Std. Dev. Std. Error
P re 12 166.291 34.687 10.013
P o st 12 129.048 33.252 9.599
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Comparison 1
Effect: Trial * Time
Dependent: glycogen
Effect: Trial * Time 
Dependent: glycogen
Comparison 2
Effect: Trial * Time
Dependent: glycogen
Cell Weight Cell Weight
placebo, Pre 1.000 CHO, Pre 1.000
placebo, Post -1.000 CHO, Post -1.000
df 1 df 1
Sum of Squares 8861.382 Sum of Squares 1216.424
Mean Square 8861.382 Mean Square 1216.424
F-Value 61.418 F-Value 8.431
P-Value .0005 P-Value .0336
G-G .0005 G-G .0336
H-F .0005 H-F .0336
Comparison 3 Comparison 4
Effect: Trial * Time 
Dependent: glycogen
Cell Weight Cell Weight
placebo, Pre 1.000 placebo, Post 1.000
CHO, Pre -1.000 CHO, Post -1.000
df 1 df 1
Sum of Squares 2342.316 Sum of Squares 117.943
Mean Square 2342.316 Mean Square 117.943
F-Value 16.235 F-Value .817
P-Value .0100 P-Value .4074
G-G .0100 G-G .4074
H-F .0100 H-F .4074
Type III S u m s o f S q u are s
Source df Sum of Squares Mear> Square F-Value P-Value G-G H-F
Subject 5 529.943 105.989
Trial 1 .002 .002 .003 .9577 .9577 .9577
Trial * Subject 5 2.678 .536
Time 1 3.082 3.082 5.208 .0713 .0713 .0713
Time * Subject 5 2.958 .592
Trial * Time 1 1.332E-15 1.332E-15 3.51 E-14 1.0000 1 1
Trial * Time * ... 6 .190 .038
Dependent; Body Weight (kg)
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Means Table 
Effect: Trial * Time 
Dependent: Body Weight (kg)
Count Mean Std. Dev. Std. Error
A, pre 6 63.000 5.265 2.150
A, post 6 62.283 4.900 2.000
B, pre 6 62.983 5.500 2.245
B, post 6 62.267 5.018 2.049
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